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Abstract Page
Background: Hepatitis C Virus is considered to be a global public health threat because 
seventy-five percent of infected persons have no symptoms and are unaware of their 
infection. It is significant to note that AI/ANs commonly contend with issues that 
prevent them from receiving or seeking medical care.
Objectives: The purpose of this study was to: (a) Characterize the level of depression, 
alcohol consumption, stigma, and quality of life; (b) Examine the relationship among the 
variables of age, gender, residing on an AI/AN reservation, current partner status, 
depression, alcohol consumption, and stigma with quality of life in a sample of AI/ANs 
living with HCV; and (c) Identify factors that explain the greatest amount of variance in 
the quality of life.
Design: A descriptive, cross-sectional, correlational design with purposive sampling of 
101 AI/AN adults with HCV from the Southwestern U.S. was implemented.
Method: Instruments used to measure the influence of variables include the Center for 
Epidemiological Studies Depression scale, Alcohol Use Disorders Identification Test, 
HCV Stigma Scale, and MOS SF-12v2 Quality of Life questionnaire.
Results: Correlational analysis indicated a statistically significant inverse relationship 
between PCS and CES-D (r = -.438, p = .000); statistically significant positive 
relationship between MCS and Age (r = .205, p = .04); statistically significant inverse 
relationship between MCS and CES-D (r = -.726, p = .000); statistically significant 
positive relationship between CES-D and AUDIT (r = .400, p = .000); CES-D and Stigma 
(r = .485, p = .000). Regression analysis indicated the overall models significantly
predicts QOL - PCS and CES-D significantly contributed to the model; QOL - MCS and 
CES-D and AUDIT significantly contributed to the model.
Implications: The identification of factors that influence QOL in HCV patients has the 
potential to give direction to the development of nursing interventions or culturally based 
care that may improve life quality in AI/AN persons living with HCV. This study will 
help to determine the level of depression, alcohol consumption, stigma, and QOL among 
AI/AN persons living with HCV. These findings have important implications for HCV 
education, treatment, AI/AN health care policy and practice improvements.
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SIGNIFICANCE OF THE PROBLEM
Hepatitis C Virus (HCV) is considered to be a global public health threat. 
Alarmingly, 75% of infected persons have no symptoms and are unaware of their health 
status. When symptoms do occur, they may be mild and indistinguishable from hepatitis 
A or B viruses (Centers for Disease Control and Prevention (CDC), 2009a). According 
to Wise, Bialek, Finelli, Bell, and Sorvillo (2008), the acute case fatality rate is low; 
approximately 75% of infected persons suffer chronic illness. In addition to the physical 
manifestations and complications, chronic HCV is also associated with neuropsychiatric 
complaints, most notably fatigue and depression. Treatment is costly, causes difficult 
side effects, but is effective in eliminating the virus and reducing liver injury in fewer 
than 50% of diagnosed cases (The Indian Health Service [IHS] Provider, 2007). 
Currently, there is no vaccine against HCV; however, in 1998, recommendations for the 
prevention and control of HCV in high-risk groups were issued (CDC, 2001).
Despite the overall successes in the fight against viral hepatitis, disparities 
continue to exist. It is significant to note that American Indian/Alaskan Natives 
(AI/ANs) commonly contend with issues that prevent them from receiving or seeking 
medical care. These issues include cultural barriers, geographic isolation, educational 
level, and financial disparities (Jones, 2006). Some of the leading diseases and causes of
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death among AI/ANs are heart disease, cancer, unintentional injuries (accidents), 
diabetes, and stroke (CDC, 2003). In addition, AI/ANs have a high prevalence and risk 
factors for mental health, suicide, obesity, substance abuse, sudden infant death syndrome 
(SIDS), teenage pregnancy, liver disease, and hepatitis (IHS, 2009; Shore & Manson, 
1983).
In 2007, AI/ANs were twice as likely to develop a case of HCV, as compared to 
the White population. In 2005, AI/ANs ages 40 years and over, were 70% more likely to 
have Hepatitis B, than non-Hispanic Whites. The data on chronic Hepatitis B and HCV 
infection (past or present) are not included by the CDC in the National Notifiable 
Diseases Surveillance System reports, because they are undergoing data quality review. 
This data is not reported in the CDC Healthy People 2010 database (Office of Minority 
Health [OMH], 2009); the National Health and Nutrition Examination Surveys 
(NHANES) do not include groups who may be considered at higher risk for hepatitis 
infection (i.e., Indigenous people, those institutionalized or incarcerated, injection drug 
using homeless populations, etc.). Therefore, the reported hepatitis data provide 
conservative estimates of disease prevalence (McQuillan et al., 2010).
The HCV infection is one of the most important causes of chronic liver disease in 
the U.S.. It accounts for about 15% of acute viral hepatitis, 60 to 70% of chronic 
hepatitis, and approximately 50% of cirrhosis, end-stage liver disease, and liver cancer 
(Institute of Medicine [IOM], 2010a). Within the U.S. population, 1.6%, or an estimated 
four million Americans, have antibody to HCV, indicating ongoing or previous infection 
with the virus. The CDC (2009e) reports that hepatitis causes an estimated 15,000 deaths 
annually in the U.S. Research conducted by Scott and Garland (2008) with aboriginal
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North Americans found that the route of transmission was similar to the general U.S. 
population and included injection drug use and blood transfusion exposure. It is 
important to also note that a well-defined and key characteristic of HCV is its tendency to 
cause chronic liver disease; the liver injury can lead to cirrhosis, liver failure, and liver 
cancer (Butt, McGinnis, Skanderson, & Justice, 2009).
Overall, the prevalence of acute HCV has declined substantially (from 5.2 cases 
per 100,000 population in 1995 to 0.5 cases per 100,000 population in 2007) among 
persons aged 25 - 39 years, the age group that historically maintained the highest rates of 
infection (CDC, 2009c). Improvements have also been made in reducing disparities in 
racial/ethnic-specific rates; during the years from 2004 - 2007 the incidence of acute 
HCV was similar across all racial/ethnic populations with the exception of AI/ANs, for 
whom rates were higher. Notably in 2007, rates were similar across racial/ethnic 
populations other than AI/ANs, for whom the rate was 0.5 cases per 100,000 populations 
(CDC, 2009d). Close monitoring of the incidence in at-risk communities remains critical 
in the detection of the disparities (Smedley, Stith, & Nelson, 2003).
Wise and colleagues (2008) propose that disease burden and mortality from HCV 
will increase in the U.S. in correlation to the increase in the numbers of persons with 
long-standing chronic infection increase. The mortality rates from 1995 - 2004 identified 
a total of 56,409 hepatitis C-related deaths. This increase was greater among males 
(144%) than females (81%), and among non-Hispanic blacks (170%) and AIs (241%) 
compared to non-Hispanic whites (124%) and Hispanics (84%) (CDC, 2009a; National 
Institute of Diabetes and Digestive and Kidney Diseases [NIDDK], 2006). Hepatitis C 
virus is an important cause of premature mortality. Despite small declines in recent
years, rates have continued to increase among persons aged 55 -64  years. This clearly 
supports the need for community-academic partnerships in research that addresses HCV 
mortality as it continues to increase substantially since 1995 (Lesser & Oscos-Sanchez, 
2007).
PURPOSE OF THE STUDY
The purpose of this study is twofold. First, it will examine the relationship 
between quality of life (QOL), depression, alcohol consumption, and stigma in this 
sample of AI/ANs living with HCV. A review of the literature revealed a need for more 
quantitative research to examine the prevalence of depression in AI/ANs living with 
HCV and compare the effects of their HCV status, stigma, alcohol consumption, and 
depression on QOL dimensions. Second, this proposed study will fill a gap in the 
hepatitis and nursing literature by describing QOL and variables of depression, alcohol 
consumption, and stigma among AI/ANs living with HCV. The results of this study will 
bring new knowledge within the context of AI/AN health and further the development a 
culturally based frameworks useful in assisting AI/AN HCV patients and health care 
providers (Giger & Davidhizar, 2007).
This is a public health priority because depression generally has been associated 
with the outcomes of chronic diseases like HCV and has contributed to the high 
economic burden of health care costs (Bailey et al., 2009; Kaiser Family Foundation, 
2009). The economic burden of HCV is directly related to the complications of cirrhosis 
and hepatocellular carcinoma (HCC). Hospitalizations account for a large proportion of 
the expenditures for HCV-related care. In 2004, approximately 419,000 hospital 
discharges in the U.S. were attributed to liver disease due to HCV (Everheart, 2008). In
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1997, an estimated $1.8 billion in medical care costs was associated with HCV infections 
(Leigh et al., 2001) while in 2011, the total healthcare cost associated with HCV infection 
was $6.5 ($4.3-$8.2) billion (Razavi et al., 2013). Total cost is expected to peak in 2024 
at $9.1 billion ($6.4-$ 13.3 billion). The majority of peak cost will be attributable to more 
advanced liver diseases—decompensated cirrhosis (46%), compensated cirrhosis (20%), 
and HCC (16%). The maximum cost associated with mild to moderate fibrosis (F0-F3) 
occurred in 2007 at nearly $780 million. The cost associated with compensated cirrhosis 
is expected to peak in 2022 at $1.9 billion, while the peak cost for decompensated 
cirrhosis and HCC is predicted to occur in 2025, with annual costs in excess of $4.2 
billion and $1.4 billion, respectively (Razavi, 2013).
Patients living with HCV have a significant decrease in their QOL, 
although treatment success can alleviate this negative effect (Rodger, 1999). The 
rate of depression amongst HCV patients (n = 157) was found to be 59%, resulting in a 
significant reduction in health-related QOL (Gallegos-Orozco et al., 2003). The World 
Health Organization (WHO, 2010) reports depression is the leading cause of disability 
worldwide; moreover, the risk of depression is greater for persons living with chronic 
HCV and a common side effect due to HCV treatment medication.
Hepatitis C is associated with reduced health related QOL as reflected in 
the disturbances of behavioral, cognitive, physical, and social aspects o f well­
being and, therefore, leads to physical and psychological problems. Quality o f life 
has also been shown to decrease in patients recently made aware of their HCV status.
The reason for this decline in QOL seen after diagnosis, in the absence of treatment, may 
be secondary to a labeling phenomenon (Rodger, 1999). Furthermore, persons with
HCV suffer from debilitating fatigue, pruritus, loss of self-esteem, depression, 
and complications of cirrhosis (Younossi, Boparai, McCormick, Price, & Guyatt,
2001).
Specific Aims:
Aim #1: Characterize the level of depression, alcohol consumption, stigma,
and quality of life among a sample of AI/ANs living with HCV.
Aim #2: Examine the relationship among the variables of age, gender, residing
on an AI/AN reservation, current partner status, marital status, 
depression, alcohol consumption, and stigma with quality of life in a 
sample of AI/ANs living with HCV.
Aim #3: Identify factors that explain the greatest amount of variance in the
quality of life of AI/ANs living with HCV.
CONCEPTUAL MODEL
The framework underlying this study is derived from the literature based on the 
concepts of QOL, depression, alcohol consumption, and stigma (Figure 1). Living with a 
HCV diagnosis can be a significant stressor for AI/AN persons and their families, social 
support system, and communities (Whitbeck, Adams, Hoyt, & Chen, 2004). The 
responsibilities and burden of living with HCV and its complications can lead to 
reactions such as psychological stress, denial, anger, and even depression (Johnson, 
Gryczynski, & Wiechelt, 2007; Neumeister et al., 2007). Over time, these responses may 
be short-lived and some patients, invariably, learn to cope with HCV and life in general. 
However, there may be some who experience prolonged and lingering feelings of stress 
and depression and are unable to adapt to living with HCV. A potential explanation for
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the development of depressive symptoms based on the Transactional Model of Stress and 
Coping, is that persons living with HCV cope differently than persons who do not 
develop symptoms of depression, anger, or stress (Lazarus & Folkman, 1984).
Figure 1 Conceptual Model: QOL in AI/AN persons with HCV
Quality of Life -  Short Form-12v2 (SF-12v2) -  The Medical Outcomes Study 
(MOS) began as a prospective, four-year observational study of the influence of 
characteristics of providers, patients, and health systems on outcomes of care. Since that 
time, several measures of health status and QOL were developed and evaluated in this 
study (Stewart, Hays, & Ware, 1988). The most widely used and best known is the SF- 
36; it uses 36 items to cover eight dimensions: physical functioning, physically related 
role limitations, social functioning, pain, vitality, mental health, emotionally related role 
limitations, and general health perceptions. The SF-12v2 was adapted from this measure 
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participants (Ware & Sherboume, 1992). The QOL of persons living with HCV has 
become increasingly important. There is now a paradigm shift in transforming goal 
therapy to improve QOL in addition to the reduction of symptoms, HCV suppression, and 
extension of survival.
Center for Epidemiologic Studies-Depression (CES-D) scale -  The CES-D was 
developed by the CES at National Institute of Mental Health (NIMH) specifically to meet 
the need for a brief, inexpensive measure of depression suitable for application in 
community surveys (McDowell, 2006; Radloff, 1957). Cognitive problems, depression 
being most common, is often overlooked in routine clinical encounters. This failure to 
recognize this problem could influence treatment outcomes for persons living with HCV 
(Horsmans, 2005). An awareness of depression’s prevalence among HCV persons and its 
potential mechanisms will encourage both patient and health care providers to be 
proactive in addressing depression affiliated with chronic HCV. The instrument is not 
explicitly tied to a theoretical framework but can screen for clinical depression in large 
epidemiological studies (Frank-Stromborg & Olsen, 1997).
Alcohol Use Disorders Identification Test (AUDIT) -  There is no theoretical 
framework that guides the AUDIT; however, this is a measure developed by the WHO as 
a screening instrument for hazardous and harmful alcohol consumption (Saunders, 
Aasland, Babor, de la Fuente, & Grant, 1993). The use of heavy alcohol consumption is 
an important cofactor in the progression of HCV-related liver disease leading to cirrhosis 
and HCC. Also, heavy alcohol consumption of more than 80 grams per day seriously 
compromises HCV illness or treatment. The NIH (2002) reports safe levels of alcohol 
consumption is unclear and that even moderate levels of consumption may accelerate
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HCV disease progression in some patients. Abstaining from alcohol is one of the most 
important factors in preserving liver health in persons with HCV, and brief assessments 
have been found to be cost-effective ways to reduce alcohol consumption. The AUDIT 
provides a simple method of early detection of hazardous and harmful alcohol use in 
primary health care settings, which makes it an appropriate measure for this study 
(Appendix F). This instrument is the first of its type to be derived on the basis of a cross­
national study (Saunders, Aasland, Amundsen, & Grant, 1993).
HCV Stigma Scale (modified) -  The concept of HCV stigma is based on the work 
of Goffman (1963), who pioneered the concept of stigma. It suggests that situations 
exist, which spoils one’s social identity. Stigma related to HCV has been found to have 
negative effects on self-esteem, access to health care, employment, social support, and 
effects on their overall health status and well-being (Crockett & Gifford, 2004). The 
standardized measure exploring HCV-related stigma in this study will utilize the HIV 
Stigma Scale (Berger, Ferrans, & Lashley, 2001); this was modified and renamed the 
HCV Stigma Scale (Appendix C) by this researcher. The discrediting attributes of which 
Goffman spoke may take the form of physical deformity, blemishes of character, and 
tribal stigma (1963). Any or all of these forms of stigma can impact persons living with 
HCV. The Transactional Model of Stress and Coping for this descriptive correlational 
study includes concepts from Medical Outcomes Study QOL Model; this provides 
understanding of chronic illnesses and related factors that affect QOL.
IMPLICATIONS TO RESEARCH, EDUCATION, PRACTICE, AND POLICY
The identification of factors that influence QOL in HCV patients has the potential 
to give direction to the development of nursing interventions or culturally-based care that
10
may improve life quality in AI/AN HCV patients (Bushy, 2008; Randall & Muneta, 
2000). This study will help to identify the level of depression, alcohol consumption, 
stigma, and QOL among AI/AN HCV patients. Additionally, the study will examine 
whether there is a relationship between depression, alcohol consumption, stigma, and 
QOL in AI/AN HCV patients. Persons with HCV may need training in coping skills to 
effectively deal with the stresses of living with hepatitis and life in general (Evans- 
Campbell, 2008; Lillie-Blanton & Roubideaux, 2005). The results of this study may have 
important implications for hepatitis education, treatment, Al health care policy, and 
practice improvements (Buffington & Jones, 2007; Lowe, 2008). Information from this 
study may help nurses develop interventions to facilitate effective coping strategies and 
improve QOL of HCV patients.
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Chapter 2 
Review o f  the Literature
The purpose of this chapter is to present a review and critique of published 
research and theoretical literature representative of the current knowledge base of QOL 
and persons living with HCV. The literature discussed here lends support to the 
significance of exploring AI/ANs with HCV as a way to further understand the 
relationships between depression, alcohol consumption, stigma, and QOL. This review 
of the literature examines the body of work and current state of the science.
The conceptual framework and underpinnings for this study is based on the 
literature and concepts of depression, alcohol consumption, stigma, and QOL. There is a 
dearth of research that collectively focuses on depression, alcohol consumption, stigma, 
and QOL within the hepatitis literature. It is through the contextual lens of QOL that this 
research can add to the science of HCV research and nursing practice. This study and its 
focused areas of concepts among HCV patients will expand on this area of scholarship 
with support of the current literature and science.
Concepts
QUALITY OF LIFE
In recent decades, there has been a broadened emphasis in the literature regarding 
QOL measurement of health outcomes. The importance of QOL ruminates beyond the 
scope of health indicators such as mortality and morbidity. This particular emphasis is
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comprised of: evaluating patient-reported functional health status’ using the Duke Health 
Profile (Parkerson, 1994); describing physical, emotional, and social function using the 
McMaster Health Index instrument (Chambers, 1993); or measuring indicator of health 
status with the MOS SF-36 Health Survey (Ware, Kosinkski, & Gandek, 2002). There is, 
however, a subjective component present within the context of defining QOL. It is those 
distinctive personal experiences and circumstances that shape an individuals’ perspective 
on QOL (Gallegos-Orozco et al., 2003; Hennessy, Moriarty, Zack, Scherr, & Backbill, 
1994). This broadened research emphasis in QOL has produced variations in general 
health status and QOL instruments. They comprise of broad concepts of well-being 
indicators to a more focused, disease-specific measures anticipated to identify clinically 
significant changes associated with specific settings (Younossi et al., 2001).
The increased number of persons, over four million in the U.S., living with HCV 
has shifted the emphasis from a health care system focused only on curative measures 
and quantity of life to enhancement of QOL (CDC, 2001; IOM, 2010b). In 2005, 133 
million Americans, approximately one out of every two adults -  had at least one chronic 
illness (Foster, 2009; Wu & Green, 2000). Moreover, the trajectory of chronic illness 
acquiesces suffering and reduces QOL (Alter, 2002; Strauss & Dias Teixeira, 2006). In 
the latter part of the 20th century, the WHO broadly defined health as a state of physical, 
mental, and social well-being not merely the absence of disease and infirmity (Grad,
2002).
The World Health Organization (1997) defines the term QOL as an individual’s 
perception of his/her position in life in the context of the culture and value systems in 
which he/she live. And, in relation to his/her goals, expectations, standards, and
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concerns. It is a broad ranging concept affected in a complex way by the person’s 
physical health, psychological state, level of independence, social relationships, personal 
beliefs, and his/her relationship to significant features of his/her environment (Bailey et 
al., 2009). Viktor Frankl (1963, 2004) asserts that QOL is tied to perception of meaning. 
This quest for meaning is central to the human condition as we are brought in touch with 
a sense of meaning when we reflect on that which we have created, loved, believed in, or 
left as a legacy.
The considerable influence on utilization of health care resources and substantial 
harm to one’s well-being has necessitated further exploration of QOL in an AI/AN HCV 
population. The CDC (2000) views QOL as a broad multidimensional concept that 
usually includes subjective evaluations o f both positive and negative aspects of life. The 
overall concept allows for an interdisciplinary focus among various disciplines and 
stakeholders to benchmark QOL as an overarching public health goal and national health 
standard of measure (NIDDK, 2006). The QOL standardized measure has many uses 
including: medication practice, research, audit, policy making, and in assessing the 
effectiveness and importance of varying treatments. It can also be beneficial in assessing 
variation in QOL across diverse populations, to compare subgroups within similar 
cultural groups and to measure differences across time in response to alteration in life 
circumstances (Stewart & Ware, 1992). The literature review regarding SF-12v2 and 
AI/ANs yielded veiy few studies but other QOL studies focusing on AI/ANs were 
identified.
A study by Johnson, Nowatzki, & Coons (1996) identified a sample population of 
Pima Indians {n = 54) living with diabetes mellitus (DM). Health status questionnaires
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were administered and QOL was measured in collaboration with an outpatient pharmacy 
in southern Arizona. The SF-36 Health Survey was utilized to assess QOL. Internal 
consistencies o f the eight multi-item scales of the SF-36 were estimated. Nonparametric 
analyses were performed to determine relationships between mean SF-36 scale scores 
and various clinical and demographic variables. Favorable internal consistencies were 
observed for the multi-item scales, with the coefficient a ranging from 0.63 to 0.91. The 
SF-36 scale scores were not influenced by sex or education level. Age was found to be 
significantly associated among four o f the eight dimensions. Indicators of glycemic 
control were not significantly associated with any SF-36 multi-item scale scores.
Subjects with more comorbid chronic conditions had significantly lower SF-36 scores.
If the goal of maximizing Al health status is to be achieved, QOL assessment should be 
utilized as a means to monitor progress toward that goal.
Another population study provided evidence of poorer QOL among Al 
participants with comorbid DM and hypertension (HTN). The relationship between QOL 
and different types of help-seeking differed depending on the comorbidity status of the 
participants. Jiang, Beals, Whitsell, Robideaux, and Manson (2009) evaluated QOL of 
AIs living with DM, HTN, or both conditions using the SF-36. They also explored how 
QOL is associated with help-seeking among AIs—with and without these chronic 
conditions. Secondary data analysis was conducted on data obtained from Al participants 
with DM and/or HTN from a larger epidemiological study of two Al tribes. The 
participants with DM and HTN had the lowest QOL on all eight subscales of the SF-36. 
Confirmatory factor analysis revealed the assumption of equivalent factor loadings for 
participants with and without DM and/or HTN was not satisfied. The usefulness of
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traditional healers (Novins, Beals, Moore, Spicer, & Manson, 2004), a form of help- 
seeking, was significantly inversely related to physical factor scores for all the 
respondents except those with DM only.
Dwight et al. (2000) concluded disability and fatigue were more closely related to 
depression severity than to hepatic disease severity. The target population consisted of 
chronic hepatitis C (CMC) patients (n = 50) being evaluated through structured interviews 
using standardized measures. The objective was to examine the extent to which fatigue 
and functional disability correlate with severity of depressive symptoms in persons with 
HCV. Bonkovsky and Woolley (1999) also evaluated the effects of CHC infection on a 
sample of patients' perceptions and whether treatment with interferon improved QOL.
The investigators concluded CHC patients with or without cirrhosis had significant 
reduction in QOL. A total of 642 patients with liver disease, enrolled in an interferon 
drug trial study for CHC, were evaluated for QOL using the SF-36 and other measures 
derived from the MOS. Persons with CHC were compared with a healthy control group 
(n = 750); the CHC group at baseline reported lower HRQOL on all eight scales of the 
SF-36 (p < .001 for all). Persons without cirrhosis (« = 284) reported similar, however, 
slightly smaller reduction in QOL. Overall, successful interferon therapy provides 
meaningful improvements in QOL in persons with CHC.
Fontana and colleagues (2002) used a large sample of CHC patients (n = 220) not 
receiving anti-viral therapy and the prevalence, type, and severity of emotional distress 
among was examined. This study involved a Brief Symptom Inventory (BSI)
(Derogatis, 1993) and a 67-item questionnaire with an embedded SF-36 instrument 
(Fontana et al., 2002). The BSI provides patient-reported data and an overview of
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patient symptoms and intensity at a specific point in time. The Global Severity Index 
(GSI) is designed to help quantify severity-of-illness and provides a single composite 
score for measuring the outcome of a treatment program based on reducing symptom 
severity (Derogatis, 1993). This study showed clinically significant emotional distress 
being reported in 35% of persons with CHC not receiving antiviral therapy. In addition 
to depression (Wessely & Pariante, 2002), a wide range of psychological symptoms was 
discerned that merits further inquiry into the causes and treatment o f emotional distress 
in persons with CHC viral illness (Palmer, 2004).
DEPRESSION
According to the diagnostic criteria described by the Diagnostic and Statistical 
Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR; American Psychiatric 
Association, 2000), major depressive disorder is defined as experiencing either depressed 
mood or loss of interest or pleasure. Along with at least four other symptoms that reflect 
a change in functioning, such as problems with sleeping, eating, energy, concentration, 
and/or self image, for a period of two weeks or longer. Clinical depression is a serious 
medical illness that is much more than temporarily feeling sad or blue. It involves the 
disruptions in mood, concentration, sleep, activity level, interests, appetite, and social 
behavior.
Although depression is highly treatable, it is frequently a life-long condition in 
which periods of wellness alternate with recurrences of illness. One area of particular 
concern is suicide (Shaffer, 1988) when depression is left untreated. According to the 
IHS (2009b), AI/ANs die at higher rates than other Americans from alcoholism (517%), 
tuberculosis (533%), motor vehicle crashes (203%), diabetes (210%), unintentional
injuries (150%), homicide (87%), and suicide (60%). The prevalence and manifestations 
contrast depending on background differences and areas of residence (Manson, Shore, & 
Bloom, 1985).
The validity of using western measures of depression has also led to a concern 
with AI/AN populations due to vast differences in cultural beliefs, mental illness, cultural 
labeling of different emotions, variability of depression manifestations (rarely DSM-IV 
criteria), and conceptual language differences (Manson, Ackerson, Dick, Baron, & 
Fleming, 1990). A study of adult AIs of a Northwest Coast Tribe demonstrated little 
differentiation between physical and emotional distress (Somervell et al., 1992). There 
are many AI/AN cultural differences that exist in seeking mental health services and in 
reporting distress. In addition, there is the much-researched phenomenon of historical 
trauma and distrust of the outside population among many AI/AN communities (Brave 
Heart, 1998; Evans-Campbell, 2008; Steinman, 2005; Weaver & Brave Heart, 1999; 
Whitbeck, Adams, Hoyt, & Chen, 2004).
AI/ANs tend to have negative opinions of non-IHS providers, and the majority of 
AI/ANs prefer the utilization of their own traditional healing practices (Rhoades & 
Rhoades, 2000). Compared to the general population, AI/AN individuals are inclined to 
underutilize mental health services, have higher therapy dropout rates, and are less likely 
to respond to treatment. The term depressed and anxious or any term relevant to a 
clinical psychological view are notably absent from most AI/AN languages and are not 
conceptualized in the AI/AN traditional health belief system. A culturally different 
expression of illness, such as ghost sickness and heartbreak syndrome, do not correspond 
to conventional DSM diagnostic criteria.
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Living in a stressful environment has potentially negative mental health 
consequences. Approximately 26% of AI/AN live in poverty, as compared to 13% of the 
general population, and 10% of Caucasian Americans. In a Northern Plains study, 61% 
of the children had experienced a traumatic event (Middlebrook, 2009). The AI/AN 
population reports higher rates of frequent distress than the general population. There is 
a high prevalence of substance abuse and alcohol dependence that is tied to a high risk for 
concurrent mental health problems. Alcohol abuse is a problem for a substantial portion 
of the AI/AN adult population, but varies widely among different tribes (National 
Alliance on Mental Illness, 2003).
The Great Smoky Mountain study found the prevalence of psychiatric disorders is 
similar among Al and Caucasian American youth in the same geographic area; however, 
there are significantly higher rates of substance abuse in Al children (Costello, Farmer, 
Angold, Bums, & Erkanli, 1997). A study of ANs in a community mental health center 
found that substance abuse was the reason for 85% of men and 65% of women to seek 
mental health care. A study by Middlebrook (2009) found that Northern Plains’ youth 
diagnosed with any depressive disorder, 60% also had substance disorders.
The prevalence of suicide is a strong indication for the necessity of mental health 
services in the AI/AN community (Bender, 2003, 2006; Borowsky, Resnick, Ireland, & 
Blum, 1999; Broderick, 2009; Pettingell et al., 2008). AI/AN males have one of the 
highest documented suicide rates in the world. Suicide rates are particularly high among 
Al males, ages 15-24, who account for 64% of all suicides by AI/AN individuals 
(Alcantara & Gone, 2007; Wissow, Walkup, Barlow, Reid, & Kane, 2001; Yoder, 
Whitebeck, Hoyt, & LaFromboise, 2006). A study of Eskimo children in Nome, Alaska,
19
found previous suicide attempts to be one of the most common problems for those 
seeking mental health care (Aoun & Gregory, 1998; Kleinfeld & Bloom, 1977).
Mental health programs are available for the AI/AN community, but are in need 
of improvement (Neligh, 1990). The IHS is a federal agency within the U.S. Department 
of Health and Human Services (U.S. DHHS) that is responsible for providing health care 
services to AI/ANs. There are 12 IHS Area Offices across the country; which oversee the 
delivery of health care services. They provide administrative and technical support and 
offer a variety of care services including mental health, alcohol and substance use 
prevention (IHS, 2008,201 la). In a large national study (the Behavioral Risk Factor 
Surveillance System), 3,940 AI/AN adults were surveyed in 36 states concerning 
drinking patterns. Respondents were compared by age and sex to non-Hispanic White 
respondents. Contrary to stereotypes, AI/AN men reported lower levels of chronic 
drinking than non-Hispanic White men at older ages. AI/AN reported less current 
drinking but about the same amount of binge drinking as non-Hispanic Whites by age and 
sex, with all groups of women reporting low levels of chronic drinking (Denny & Taylor, 
2001).
Depression is a common and highly treatable disorder affecting over 17-20 
million Americans annually. When left untreated and/or under-treated, depression is the 
leading cause of suicide in the U.S. (IOM, 2002; Substance Abuse and Mental Health 
Services Administration (SAMHSA), 2011). Once identified, depression can almost 
always be successfully treated. Unfortunately, there is limited information available 
about the prevalence of mental illness between AI/AN~more specifically women. The 
two major studies conducted—The Epidemiologic Catchment Area Study and the
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National Comorbidity Survey—did not report data on AI/ANs. The prevalence among 
AI/AN populations are problematic because they may be susceptible to unique factors 
that may affect their vulnerability to mental illness (Brave Heart & DeBruyn, 1998). 
Awareness and knowledge is the first step to prevention and successful treatment.
Available evidence suggests mental illnesses impact approximately 20 percent of 
the total AI/AN population. The overall mental health picture for AI/ANs is not fully 
documented; previous studies are restricted by small sample sizes, limited funding, racial 
misclassification, and a focus on specific conditions (SAMHSA, 2011). In the AI/AN 
population, high lifetime risk rates of substance use disorders, anxiety disorders, and low 
socioeconomic conditions combine to give context to the greater risk for the development 
of depression (Dickerson & Johnson, 2010).
Many minority women experience depression and stress brought on by persistent 
racism, gender bias, violence, poverty, large family size, and social disadvantages. Yet, 
access to culturally relevant therapy is rare; access to qualified mental health services is 
poor, and the quality is poor. According to the 2001 Surgeon General’s report minority 
women with access to mental health services are less likely than White women to use 
them for reasons related to income and availability of health insurance, but also personal 
history and culture (U.S. DHHS, 2001). Duran et al. (2005) state among minority 
women, there is greater tendency to engage in other informal sources of help, such as 
prayer or support groups where women gather and talk with friends, hoping to gain what 
others often gain by having individual therapy. The main cause for not seeking outside 
treatment is lack of trust (Lowe, 2008).
Another reason minority women do not seek formal therapy is because of their
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respective cultures. There are other ways of regaining a sense of peace and well-being. 
Native American women and women of Alaskan descent often rely on traditional healers 
(Randall & Muneta, 2000), who may work side by side with formal health providers in 
tribal mental health programs. AI/AN women have access to some mental health care 
services through IHS on their reservations, though finding culturally competent services 
can be a challenge.
The CES-D scale (Radloff, 1977) is a 20-item self-report questionnaire developed 
to measure and identify symptoms of depression or psychological distress in community 
populations (Myers & Weissman, 1980; Roberts & Vernon, 1983). The composited 
items were selected from previously validated scales and cover the major components of 
depressive symptomatology. The general population were being defined as non­
psychiatric persons over the age of 18. At the time of its development, researchers were 
interested in the health correlates of depressive symptoms and in tracking changes in 
severity of symptoms over time.
The scale has also been applied in many studies as a screen for the presence of 
depressive illness. Items were selected to represent the major components of depression 
on the basis of the clinical literature and factor analytic studies. It was designed to gauge 
the major components of depression that includes depressed mood, feelings of guilt and 
worthlessness, feelings of helplessness and worthlessness, psychomotor retardation, loss 
of appetite, and sleep disturbance.
It is not a clinical diagnostic measure for a depression diagnosis because it only 
assesses symptoms presenting in the past week and does not assess the complete range of 
depressive symptoms. However, it can be used as an indicator of symptoms. It is also an
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important measure for recognizing groups at-risk for depression, as well as the links 
between behavior and depressive symptoms (Breslau, 1985). It has been developed in 
the recognition of depressive symptoms in the general population; research supports the 
utility of the CES-D scale in assessment studies, and as a screening tool.
The scoring of CES-D begins with participants answering items about the 
regularity and length of depressive moods, thoughts, or feelings in the past week. 
Participants are asked to rate each item using a 0 to 3-response scale; except for the four 
positive questions, on how often you have fe lt this way during the past week. A 0 
response means rarely or none o f  the time (less than 1 day), 1 means some or a little o f  
the time (1-2 days), 2 means occasionally or a moderate amount o f time (3—4 days), and 3 
means most or all o f  the time (5-7 days). In order to control for response bias, four items 
(#4, 8,12, and 16) were worded in a positive direction.
The scores are summed to provide an overall score ranging from 0 to 60; higher 
scores indicate more severe depressive symptoms. The total severity is calculated by 
reverse scoring questions #4, 8,12, and 16 (the items that control for response bias) and 
then summing all of the scores. A score of 16 or higher has been identified in early 
studies (Weissman, Sholomskas, Pottenger, Prusoff, & Locke, 1977) and commonly 
taken as indicative of depressive illness. They represent a range of depressed mood, from 
average mood levels to high levels of depressed mood. If one’s mood score is high, they 
are more likely to have trouble controlling other aspects of their life. An example would 
be that, a person might be at risk of abusing alcohol, tobacco, or other drugs excessively. 
Therefore, their score may serve, as a reminder that they need to learn to control their 
mood in other ways if one wants to be successful in living a healthier life.
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The interpretation of a CES-D score of less than 16 indicates clearly within the 
average range of scores for adults in the U.S. that depressed mood does not seem to be a 
current issue. Whereas, scores ranging from 16 to 24, suggests borderline elevation of 
depressed symptoms, compared to other adults. While depressed mood may be a source 
of concern, and it may be worthwhile to learn methods to manage mood to prevent the 
level of depression from getting worse (Lewinsohn, Mufioz, Youngren, & Zeiss, 1992; 
Munoz, 1996). And, scores 24 or above would suggest a significant elevation of 
depressed symptoms and compared to others, it would be essential to decrease the level 
of depression.
The CES-D reliability and validity has been tested in African American, Asian 
American, French, Greek, Hispanic, Japanese, and Yugoslavian populations (Naughton & 
Wiklund, 1993). It has also been translated into several languages, including Chinese 
(Cantonese and Mandarin), French, Greek, Japanese, and Spanish. The internal 
consistency as measured by Cronbach a is high across a variety of populations (generally 
around 0.85 in community samples and 0.90 in psychiatric samples) (Boyd, Weissman, 
Thompson, & Myers, 1982; Husaini, Neff, Harrington, Hughes, & Stone, 1980). Split- 
half reliability is also high, ranging from 0.77 to 0.92. Test-retest reliability studies 
ranging over 2—8 weeks show moderate correlations (r = 0.51- 0.67), which is desirable 
for a test of symptoms expected to show change over time. One study comparing African 
American, Anglo-American, and Mexican American respondents showed no difference 
in measures of internal consistency reliability (Roberts, 1980). The validity of CES-D in 
an outpatient setting sample with depression, alcoholism, drug addiction, or 
schizophrenia has been examined. The correlation coefficients (r) between CES-D scores
24
and Symptom Checklist-90 (SCL-90), depression subscale scores were high, ranging 
from 0.73 to 0.89. Correlations with the Hamilton Rating Scale for Depression (Ham-D) 
scores were variable and ranged from 0.49 for patients with acute depression to 0.85 for 
patients with schizophrenia. Correlations with the Raskin Scale were also variable, 
ranging from 0.28 for patients with acute depression to 0.79 for patients with 
schizophrenia (Weissman et al., 1977).
It should be noted that CES-D scores differ widely depending on one’s condition 
in society. For example, although the mean score on the CES-D is 8.7 for people aged 25 
to 74, women tend to score higher than men. Moreover, among individuals living alone, 
the average CES-D score for men and women is 8.5 and 10.8, respectively. This is in 
contrast to people living with others showed that, the average CES-D score for men and 
women is 6.8 and 9.3, respectively. Interestingly, the average for women who are heads 
of households is 12.5. People with less education and lower income tend to score higher 
(Sayetta, 1980). An assessment of the aging population using the CES-D evaluated 
subsets of the original population including persons older than 64. The coefficient a 
remained high (> 0.85) in this subgroup and test-retest correlations remained > 0.40. For 
assessment of the measure in minority populations, the CES-D was evaluated for subsets 
of the original population including Blacks. The coefficient a remained high (> 0.85) in 
this subgroup; test-retest correlation was < 0.40 for this group (Radloff, 1977). Group 
means should only be used in reference to other groups. The internal reliability and 
consistency is good for all groups tested (race, age, education). The CES-D design 
strengths and weaknesses clearly show it is not intended as a clinical diagnostic tool and 
that interpretations of individual scores should not be made (Radloff, 1977).
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Chapleski, Lamphere, Kaczynski, Lichtenberg, and Dwyer (1997) utilized the 
Center for Epidemiological Studies Depression Scale (CES-D) in a study of 309 Great 
Lakes Al elders from urban, rural, and reservation settings, with good internal 
consistency (Curyto et al., 1998). This study also supported earlier findings of an 
association between stressful life events, depressive symptoms, and decline in functional 
health status. Depression is among the most prevalent psychopathologies within AI/AN 
communities, but little is known about the validity and reliability of common assessment 
measures in this population. Beals, Manson, Keane, and Dick (1991) describes the factor 
structure of the CES-D scale, which was based on collected data from a sample (n = 605) 
of Al college students. Comparisons of the factor structure across gender indicated 
differences were due largely to one item: crying. A 3-factor model fit the data well and 
was judged the most parsimonious.
A clarified conceptual meaning of depression in individuals with HCV infection 
is proposed based on a critical review of literature. Moving beyond an exclusively 
biomedical perspective, depression in HCV is explained by a cluster of factors that 
incorporate physiological, psychological, and social dimensions. Symptom experience, 
stigma, and uncertainty are factors that span the complex nature of depression in persons 
with HCV. This broadened perspective incorporates individual and societal values and 
beliefs regarding HCV and encompasses the multidimensional complexity of depression 
in HCV. Hepatitis C-related depression presents an enormous challenge for nurses 
because of its interference with treatment adherence and significant negative impact on 
the person’s QOL (Gallegos-Orozco et al., 2003). Nursing theorists, researchers, and 
clinicians may benefit from a clear conceptual understanding of the unique nature of
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depression in this growing segment of the U.S. population. This clarified conceptual 
meaning needs to be examined through qualitative, quantitative, and longitudinal studies 
with this population. It is hoped that future theorists, researchers, and practitioners will 
contribute to the conceptual understanding, resulting in improved QOL for this special 
population (Saunders & Cookman, 2005).
Although the incidence of HCV is declining, a large reservoir of patients with 
CHC exists. Unless effective HCV antiviral regimens are developed, many patients with 
asymptomatic HCV may develop clinical symptoms in 15 to 20 years. Mood disorders 
are common in patients with HCV who are referred for psychiatric consultation. The 
drug interferon and ribavirin are the primary treatment for CHC but can induce 
depression and other mental and neuropsychiatric syndromes. Mood disorders associated 
with HCV may respond to psychiatric intervention (Dolan, 1999; Yates & Gleason,
1998).
A veteran focused study examined the incidence of psychiatric comorbidities 
among veterans {n = 120) with CHC. This study assessed depression, anxiety sensitivity, 
post-traumatic stress symptoms, and alcohol consumption using standardized measures in 
veterans with chronic HCV. Lehman and Cheung’s (2002) research revealed psychiatric 
comorbidities to be very common among veterans with chronic HCV and correlated 
poorly with diagnoses documented in the medical record. In chronic HCV veterans, 
clinically significant levels of depression (44.2%), anxiety (38.1%), post-traumatic stress 
disorder (20.8%), and alcohol-related problems (26.7%) were observed. Positive 
correlations were found between post-traumatic symptoms and depressive symptoms, 
anxiety sensitivity, and alcohol use problems (Nelligan et al., 2008). A correlation
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between depressive symptoms with anxiety was also identified. Overall, 79 (65.8%) 
veterans had one or more possible contraindications to antiviral therapy: coexisting 
unstable psychiatric disorders, and/or recent substance use was found in 73.4% of these 
veterans. An implication for this study is a multidisciplinary approach that includes 
psychological assessment using standardized measures in the evaluation of these patients 
for antiviral therapy.
Another study examined CES-D scale reliability, construct, and predictive 
validity in a HCV patient sample (n = 116) of 62 (53%) males and 54 (47%) females.
This longitudinal study tested the CES-D psychometric properties at three time intervals: 
prior to treatment, at four weeks, and 24 weeks post treatment. Clark, Mahoney, Clark, 
and Eriksen (2002) concluded that the CES-D is a reliable and valid instrument to screen 
for depressive symptoms in HCV patients. The instrument is able to detect the predicted 
increase in depression associated with HCV. However, an examination of the sensitivity 
and specificity is needed to determine the most accurate cut-off score. The reliability 
(Cronbach a) = 0.88 Pretreatment, 0.89 Week 4, and 0.90 Week 24. The construct 
validity revealed four factors: negative affect, positive affect, somatic affect, and 
depressed affect. With the exception for two items, felt sad and couldn't get going, all 
items loaded distinctly with correlation coefficients in the range of 0.51 -  0.84. The 
predictive validity testing revealed a statistically significant effect over time {p < 0.001) 
in the direction predicted (pretreatment x = 13.97; post 4 weeks x = 19.54, and 24 weeks 
x = 19.97) (Clark et al., 2002).
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ALCOHOL CONSUMPTION
The patterns of alcohol consumption and its consequences differ considerably 
among minority groups. Although more research is needed, evidence supports 
prevention and treatment efforts may be more effective when based on cultural 
understanding of the ethnic / cultural contexts of drinking behaviors and their 
development (Botvin, Schinke, Epstein, Diaz, & Botvin, 1995; Kumpfer, 1998). It is 
important to note the uniqueness of racial/ethnic populations including AI/AN 
communities, which differ markedly in cultural characteristics and drinking behavior. 
Consequently, research does not support broad generalizations about specific 
subpopulations, many of whom have not been studied individually (Beauvais, 1998; 
Caetano, Clark, & Tam, 1998).
Data from nationwide surveys o f adults show that both current drinking (defined 
as consumption of 12 or more drinks in the past year) and heavy drinking are most 
prevalent among AI/ANs and Native Hawaiians and lowest among Asian American and 
Pacific Islanders (AAPIs) (Kim, Coletti, Williams, & Hepler, 1995). Among all age and 
ethnic groups, men are more likely to drink than are women, and to consume large 
quantities in a single sitting. Heavy alcohol consumption is defined as five drinks on a 
single day at least once a month for adults and five drinks in a row at least once during 
the previous two weeks for adolescents (Johnston, O'Malley, & Bachman, 2001; Stinson 
et al., 1998).
The medical consequences and research on alcohol's health effects on minority 
groups has concentrated largely on cirrhosis, a progressive and often fatal liver disease 
usually attributable to long-term heavy drinking (NIDDK, 2006). Analysis shows a
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strong correlation between death rates from liver cirrhosis, regardless of cause, and 
drinking levels nationwide (Singh & Hoyert, 2000). Consistent with this association, 
deaths from chronic liver disease and cirrhosis are approximately four times more 
prevalent among AI/ANs than among the general U.S. population (Beauvais, 1998).
Data from a nationwide survey highlights the social consequences of drinking and 
driving prevalence in the past year: 19% among AI/ANs, 11% for both Whites and 
Hispanics, 7% for African Americans, and less than 6% for AAPIs (Stinson et al., 1998). 
Alcohol-related fatal crashes are three times more prevalent among AI/ANs than among 
the general population (Beauvais, 1998), constituting 1 of the 10 leading causes of death 
among AI/ANs, along with alcohol-related suicide, homicide, and cirrhosis (Grossman, 
Sugarman, Fox, & Moran, 1997).
The Alcohol Use Disorders Identification Test (AUDIT) is an instrument 
designed to identify persons with HCV and assess their hazardous and harmful patterns 
of alcohol consumption. The WHO developed the AUDIT as a simple method of 
screening for excessive drinking and to assist in brief assessment. This measure was 
developed and evaluated over a period of two decades, and has been found to provide an 
accurate measure of risk across gender, age, and cultures (Volk, Steinbauer, Cantor, & 
Holzer, 1997). It can assist in identifying excessive drinking as the cause of the 
presenting illness.
It also provides a framework for intervention to help hazardous and harmful 
drinkers reduce or cease alcohol consumption and, thereby, avoid the harmful 
consequences of their drinking. The AUDIT also helps to identify alcohol dependence 
and some specific consequences of harmful drinking. It is particularly designed for
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health care practitioners and a range of health settings, but, with suitable instructions, it 
can be self-administered or applied by non-health professionals (Allen, Reinert, & Volk, 
2001).
STIGMA
Today, it is an increasingly acknowledged global reality that those most deeply 
affected by the HCV epidemic are also severely disadvantaged, whether based on race, 
gender or sexual orientation, age, or social class (International Council of Nurses (ICN), 
2003; WHO, 2001). In addition to the physical challenges HCV presents, this illness 
carries with it a stigma that negatively impacts QOL for infected persons. The impact on 
affected persons consists of psychological stress, reduced self-esteem, depression, fear of 
disclosing HCV status, worsening disease state resulting in limited social support systems 
and resources (Astone-Twerell, Strauss, & Munoz-Plaza, 2006; Van Brakel, 2006). The 
landmark Surgeon General’s Report on Mental Health identifies stigma as a public health 
concern, providing leverage for advocacy (Link & Phelan, 2006; U.S. DHHS, 1999). As 
in the case of most other stigmatized health conditions such as HIV/AIDS, mental illness, 
and sexually transmitted infections, fundamental structural inequalities, social prejudices, 
and social exclusion explain why women, the homeless, veterans, substance users, sexual 
minorities, and people of color are disproportionately impacted by HCV and the 
accompanying stigma and discrimination (IOM, 2010a).
The nearly two decade of global history of the HCV epidemic reinforces the well 
documented interaction of disease, stigma, and 'spoiled’ social identities (Goffman,
1963) based on race, ethnicity, sexuality. In attempting to further understand AI/ANs 
living and experiencing HCV-related stigma, it is edifying to refer to the concept of
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stigma based on Goffman’s scholarly work. Stigma is a term with a multitude of 
connotations and definitions. The concept of stigma first emerged within the social 
science research through the seminal work of Erving Goffman.
Goffman (1963) defined stigma as an attribute that is deeply discrediting and 
reduces the bearer from a whole person to a tainted, discounted one. It is seen among 
individuals’ who are newly diagnosed with HCV and often judge themselves harshly.
This diagnosis can bring on feelings or emotions of shame and uncleanliness. According 
to the Oxford Dictionaiy (2011), the definition of stigma is a mark o f  disgrace associated 
with a particular circumstance, quality, or person. The Greek and Latin origins of 
stigma also means to mark, brand, or tattoo. Merriam-Webster Dictionary (2011) 
describes stigma as a mark o f shame or discredit; an identifying mark or characteristic; a 
specific diagnostic sign o f  a disease.
In general, individuals often first learn about HCV through negative media or 
images and adopt misinformation about the modes o f HCV transmission. Because many 
individuals who may inject drugs have HCV, there is often an automatic association 
between HCV and injection drug use. It is due to these assumptions and 
mischaracterizations towards the injection drug user that this association can lead to 
stigma. Link and Phelan (2001) posit that stigma exists when a label sets the person apart 
and links the person to undesirable stereotypes resulting in unfair treatment and 
discrimination. Stigma related to HCV illness can have profound negative impacts on an 
individual’s personal and social relationships, workplace environment, community, and 
access to health care. Stigma occurs when individuals are negatively judged and/or 
discredited because they have HCV.
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An exemplary research study by Buseh, Kelber, Stevens, and Park (2008) 
explored the relationship of symptom prevalence and intensity, perceptions of health, and 
stigma on QOL. This cross-sectional correlational descriptive study consisted of a 
sample of (n = 55) HIV-infected African Americans, all urban, age ranging 23-66 years 
(M= 48.84, SD = 7.67), and average length of time since HIV diagnosis 10.79 years (SD 
= 6.4). The measures consisted of 5 instruments: (a) sociodemographic characteristics, 
(b) Holzemer Signs and Symptom Checklist for HIV (Holzemer, Hudson, Kirksey, 
Hamilton, & Bakken, 2001), (c) a perception of health single-item question, (d) HIV 
Stigma Scale (Berger, Ferrans, & Lashley, 2001), and (e) Holmes’ HIV/AIDS-Targeted 
QOL Scale (Holmes & Shea, 1998).
The most prevalent symptoms were fatigue (98%), fear (92.7%), shortness of 
breath (92.7%), gastrointestinal upset (85.5%), numbness (80.0%), and headache 
(76.4%). Symptoms with the highest reported prevalence and greatest intensity were 
gastrointestinal upset, body changes, fear, and fatigue. The intensity of symptoms was 
significantly correlated with measures of stigma (r = .320, p  <.025) and QOL (r = -.425, 
p  <.002). This study emphasizes the importance of incorporating a holistic view of the 
relationship of symptoms with QOL (Buseh et al., 2008).
Franke and colleagues (2010) conducted a study to validate a Spanish version and 
create a valid and reliable abridged version of the Berger HIV Stigma Scale in an urban 
Spanish-speaking population in Peru. The Spanish version of the full HIV Stigma Scale 
was shown to be internally reliable, demonstrated good construct validity, and was 
sensitive to change over time. This was an observational study in whcih HIV-infected 
adult participants were enrolled in order to examine the effectiveness of a community-
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based antiretroviral therapy adherence intervention. Approximately half of participants 
were female, and the median age at enrollment was 30.5 years. The full HIV Stigma 
Scale was abbreviated, containing 21 of the 40 original items, and revealed properties 
similar to the full Spanish version (Franke et al., 2010).
Moore, Hawley, and Bradley (2009) set out to identify and categorize stigmas 
associated with HCV. This was a qualitative approach consisting of a sample (n = 39) of 
participants' written narratives describing stigmatic events. These narratives were in 
response to a question that incorporated a functional definition of stigma that was 
completed during support group meetings. Approximately 85% experienced hepatitis C- 
related stigma and these findings expanded current knowledge of the stigma 
complexities. Upon qualitative data saturation, a total of five themes and 16 concepts 
emerged. Nursing practice implications consisted of a comprehensive structural and 
institutional application of policy. Also, population and peer education about HCV and 
potential stigma would be a worthy opponent to the problem at hand.
Interventions to reduce stigma are crucial for improving care, QOL, and 
emotional health for AI/ANs living with HCV. Extant research has shown that stigma 
can be lessened through an array of intervention strategies that include increasing 
knowledge and community awareness about HCV, counseling treatment, acquiring new 
coping skills, and/or increasing contact with infected or affected individuals (Brown, 
Macintyre, & Trujillo, 2003).
CONCEPTUAL MODEL
The framework underlying this study is derived from the literature based on the 
concepts of QOL, depression, alcohol consumption, and stigma (Figure 1). Living with a
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HCV diagnosis can be a significant stressor for AI/AN persons and their families, social 
support system, and communities (Whitbeck, Adams, Hoyt, & Chen, 2004). The 
responsibilities and burden of living with HCV and its complications can lead to 
reactions such as psychological stress, denial, anger, and even depression (Johnson, 
Gryczynski, & Wiechelt, 2007; Neumeister et al., 2007). Over time, these responses may 
be short-lived and some patients, invariably, learn to cope with HCV and life in general. 
However, there may be some who experience prolonged and lingering feelings of stress 
and depression and are unable to adapt to living with HCV. A possible explanation for 
the development of depressive symptoms in patients with HCV is based on the 
Transactional Model of Stress and Coping, in that, persons who develop depressive 
symptoms may cope with HCV differently than persons who do not develop symptoms of 
depression, anger, or stress (Lazarus & Folkman, 1984).
M odel
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HCV, Comorbidities, 
Antiviral tX (interferon/ 
ribavirin)
Figure 1 Conceptual Model: QOL in AI/AN persons with HCV
35
In summary, this chapter presented a review and critique of published research 
and theoretical literature that is representative of the current knowledge of QOL, 
depression, alcohol consumption, and stigma. The literature discussed lends support to 
the importance of continuing to examine these relationships so that culturally appropriate 
interventions may be developed to improve life quality in AI/AN persons living with 
HCV. Through the contextual lens of QOL, this research can further add to the science 
of HCV research and practice. This study and its focused areas of concepts among HCV 





The purpose of this chapter is to describe the methodology employed in this 
study, to explore the relationships among depression, alcohol consumption, stigma, and 
QOL among AI/AN adults living with HCV. The theoretical perspectives and 
underpinnings for this research study are based on QOL, depression, alcohol 
consumption, and stigma. This study aims to advance our understanding of the 
measurement of QOL among AI/AN HCV patients. This chapter will describe the 
research design, population and sample, instrument procedures, data collection 
approaches, data analysis strategies, and the protection of human subjects.
Specific Aims:
Aim #1: Characterize the level o f depression, alcohol consumption, stigma,
and quality of life among a sample of AI/ANs living with HCV.
Aim #2: Examine the relationship among the variables of age, gender, residing
on an AI/AN reservation, current partner status, marital status, 
depression, alcohol consumption, and stigma with quality of life in a 
sample of AI/ANs living with HCV.
Aim #3: Identify factors that explain the greatest amount of variance in the
quality of life of AI/ANs living with HCV.
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DESIGN
A descriptive, correlational, cross-sectional survey design was used for this study. 
The goal of a descriptive correlational approach is to describe the data collected and 
relationships that exist among variables in a situation. Descriptive studies are aimed to 
find out what is, so observational and survey methods are frequently exercised to collect 
descriptive data (Borg & Gall, 1989). Descriptive studies facilitate reporting summary 
data on measures of central tendency that includes the mean, median, mode, and deviance 
from the mean, variation, percentage, and correlation between variables. The cross- 
sectional survey research design often goes beyond the descriptive statistics in order to 
draw inferences (Mertler & Vannatta, 2002; Vogt, 2005).
SAMPLE
A purposive sample of individuals who are receiving health care services for their 
HCV disease were recruited from two health care programs serving AI/ANs in the 
Southwest region of the U.S. The inclusion criteria for this study consists of: a confirmed 
diagnosis of HCV with detectable HCV RNA levels at the beginning of medical 
treatment; may or may not be undergoing antiviral therapy with interferon and/or 
ribavirin; ability to read and comprehend English; ability to comprehend and complete 
study instruments; and voluntary willingness to participate in the research study. The 
exclusion criteria include: less than 18 years of age; psychiatric or medical disturbance 
that impedes full participation and informed consent process; or a potential participant’s 
decision to decline research study participation.
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SAMPLE SIZE
Sample size was determined by power analysis applying a small effect size of 0.3, 
level of significance (a = .05), with a statistical power = .80. The desired sample size (n 
= 82) for this study was calculated using Power and Precision 4 developed by Borenstein, 
Hedges, Rothstein, Cohen, & Schoenfeld (2010). Power is the probability of detecting a 
particular effect size, given a specific alpha level and is determined by sample size, 
measurement error, alpha level, effect size, and number of control variables. A power of 
.80 or greater is desirable (Borenstein, Rothstein, Cohen, Schoenfeld, Berlin, & Lakatos, 
2000).
SETTING
The research setting for participant recruitment was at two health care programs 
serving AI/ANs in the areas of Southern California and Southwest Arizona. The first site 
consists of a tribal health care clinic providing a full spectrum of on-site and outreach 
services and programs to their communities and other AI/ANs residing within their 
catchment area. Site 2 is a facility funded directly by IHS and provides services to more 
than 35,000 AI/ANs within their catchment or service area unit. The second site consists 
of a hospital and provides comprehensive care ranging from primary care (inpatient & 
outpatient) to tertiary care and specialty services. These site locations are considered 
ideal, target communities to this investigator’s research study.
PROTOCOL/ PROCEDURES
A collaborative effort with the clinic health care providers and medical staff was 
established to assist with identification and recruitment of potential study participants and 
obtain informed consent. When a potential participant had been identified, this
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investigator and/or health care staff provided an overall description and purpose of the 
research study. The participant(s) were informed about what would be gleaned from this 
research study’s findings and how it has the potential for future programmatic 
development and community education focusing on improved HCV services.
The primary investigator was available to answer questions. Participants were 
informed that the standard of care would not be altered should they decide to not 
participate in this research study. An attempt to recruit adult participants of various age 
groups, equal number of gender, and a varied representation of AI/ANs who receive 
health services within these study sites. Recruitment included: (1) an invitation letter for 
study participation and research participant consent form; (2) an opportunity to review, 
ask questions, and (3) to choose to participant by signing the informed consent.
Participants who signed informed consent were interviewed by the primary 
investigator for approximately 60 minutes. This was to ensure that all survey instruments 
were completed at a time and setting appropriate, convenient, and private for the 
participants. A monetary incentive was provided in the form of a gift card or cash to 
acknowledge the participant’s time and participation (Appendix N and O). On 12 
February 2011, the principal investigator completed the NIH Office of Extramural 
Research course in “Protecting Human Participants” prior to obtaining Institution Review 
Board (IRB) approval. The research study packet included: an Invitation Letter for Study 
Participation (Appendix H and I) explaining the research study and invitation; a Letter of 
Support from the healthcare organization’s Executive Officer and/or IRB Chairperson 
(community / cultural stakeholders) (Appendix A and B); a Research Participant Consent 
Form and Projectal Subject’s Bill of Rights (Appendix J, K, L, M); four standardized
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instrument questionnaires (Appendix P, Q, R, S), and Personal and Clinical Data 
Collection form (Appendix T and U).
DATA COLLECTION
Approval was obtained from the University o f San Diego IRB (Appendix C and 
D) and two study sites (Appendix E, F and G), respectively. The primary investigator 
met with eligible participants after their scheduled clinic appointments to explain the 
research study and to answer questions. The participants who agreed to participate were 
provided an opportunity to review and sign the research study informed consent form. 
Research data were de-identified with a coded number assigned by the primary 
investigator and data were securely stored.
INSTRUMENTS
Each of the key constructs in the proposed model were measured using self-report 
instruments. In the following section, a description of each of the instruments utilized to 
measure QOL, depression, alcohol consumption, and stigma is provided. Instruments 
were selected on the basis of their applicability for self-report, reliability and validity, and 
limited response burden. Demographic characteristics and clinical factors related to HCV 
are also described.
Quality of Life - Short Form-12v2 (SF-12v2) - The outcome variable, QOL will 
be measured using the SF-12v2 questionnaire, which has been widely implemented in 
social and psychological research. A 12-item instrument, the SF-12v2, is one of several 
multipurpose health surveys that measures health status and was constructed from a 
subset of 149 core items developed during the Medical Outcome Study (Stewart & Ware, 
1993). The physical component subscale (PCS) is an overall measure of physical health
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and a reflection of an individual’s satisfaction with their perceived level of physical 
function, mobility and role limitations due to their health status. The mental component 
subscale (MCS) is an overall measure of mental health impacted by depression, sense of 
well-being, and the ability to participate in social activities.
The SF-12v2 is a 12-item subset from the SF-36v2 and has demonstrated 
equivalent mean scores for the physical and mental component subscales of HRQOL 
among general and disease-specific populations (Scientific Advisory Committee of the 
Medical Outcomes Trust, 2002; Ware, Kosinski, Tumer-Bowker, & Gandek, 2002). This 
instrument measures the same eight health domains: Physical Functioning, Role-Physical, 
Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental 
Health (Fleishman, Selim, & Kazis, 2010).
The SF-12v2 reproduces more than 90% of the variance of the PCS and MCS of 
the SF-36 in the general U.S. population, takes significantly less time to complete than 
the SF-36, reducing burden on research participants, and demonstrated high two-week 
test-retest reliability correlations for both PCS (r -  0.89) and MCS (r = 0.76). Applied 
extensively in HRQOL research, the SF-12v2 survey is convenient, may be completed in 
less than two minutes, to monitor health changes, or analyze and compare disease burden 
in the general population (Cheak-Zamora, Wyrwich, & McBride, 2009). The subscales 
of the SF-12v2 have been found to be internally consistent with reported Cronbach a of 
.87 (PCS) and .82 (MCS), respectively.
Center for Epidemiologic Studies-Depression (CES-D) scale - The CES-D scale 
(Radloff, 1977) is a 20-item self-report questionnaire developed to measure and identify 
symptoms of depression or psychological distress in community populations (Myers &
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Weissman, 1980; Roberts, Vernon, & Rhoades, 1989). The CES-D Questionnaire (vl.O), 
although it may be pragmatic to identify populations at risk of developing clinical 
depression or anxiety disorders, is not intended as a clinical diagnostic tool (Radloff, 
1977). Since its introduction, the CES-D has been practical to assess depression risks in 
several populations (e.g., adolescent, elderly, ethnic and clinical populations) for whom it 
was not originally designed.
The 20-item scale measures the following six components: depressed mood, 
feelings of guilt and worthlessness, feelings of helplessness and hopelessness, 
psychomotor retardation, loss of appetite, and sleep disturbance (Radloff, 1977). The 
participants are asked to indicate how frequently they experienced the symptom within 
the past year on a scale ranging from rarely or none of the time to most or all of the time. 
Each frequency level on the CES-D is assigned a numerical score ranging from 1 to 4.
The CES-D has been shown to be a reliable measure for assessing the number, 
types, and duration of depressive symptoms across racial, gender, and age categories 
(Knight, Williams, McGee, & Olaman, 1997; Radloff, 1977; Roberts, Vernon, & 
Rhoades, 1989). A high internal consistency has been reported with Cronbach’s a  
coefficients ranging from .85 to .90 across studies (Radloff, 1977). Concurrent validity 
by clinical and self-report criteria, as well as substantial evidence of construct validity has 
been demonstrated (Radloff, 1977). However, there is evidence that the CES-D, while a 
useful measure of the level of depressive symptoms, may not be a good tool for screening 
for clinical depression or major depression (Roberts, Vernon, & Rhoades, 1989).
Alcohol Use Disorders Identification Test (AUDIT) - The AUDIT is an 
instrument designed to identify persons with HCV and assess their hazardous and
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harmful patterns of alcohol consumption. The WHO developed the AUDIT as a simple 
method of screening for excessive drinking and to assist in brief assessment. This 
measure was developed and evaluated over a period of two decades, and it has been 
found to provide an accurate measure of risk across gender, age, and cultures (Voik et 
al., 1997).
It can assist in identifying excessive drinking as the cause of the presenting 
illness. It also provides a framework for intervention to help hazardous and harmful 
drinkers reduce or cease alcohol consumption and, thereby, avoid the harmful 
consequences of their drinking. The AUDIT facilitates the identification of alcohol 
dependence and some specific consequences of harmful drinking. It is particularly 
designed for health care practitioners and a range of health settings, but, with suitable 
instructions, it can be self-administered or used by non-health professionals (Allen et al., 
2001).
To score the AUDIT, each of the questions has a set of responses to choose from, 
and each response has a score ranging from 0 to 4. The AUDIT consists of 10 items that 
can be administered quickly either verbally, written, or by computer in five minutes. 
Scoring: Questions 1 through 8 are scored 0, 1, 2, 3, or 4 points. Whereas, questions 9 
and 10 are scored 0,2, or 4 points. A score of 8+ on the AUDIT generally indicates at- 
risk, harmful, or hazardous drinking (Allen, Litten, Fertig, & Babor, 1997).
In the interview format, the interviewer records the score that corresponds to the 
patient’s response in the box beside each question (Bohn, Babor, & Kranzler, 1995). All 
the response scores are added and a Total score is recorded. The AUDIT can detect 
alcohol problems experienced in the last year. Total scores of eight or more are
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recommended as indicators of hazardous and harmful alcohol use, as well as possible 
alcohol dependence. A cut-off score of 10 will provide greater specificity but at the 
expense of sensitivity (Volk et al., 1997). Since the effects o f alcohol vary with average 
body weight and differences in metabolism, establishing the cut off point for all women 
and men over age 65 one point lower at a score of 7 will increase sensitivity for these 
population groups.
Based on experience gained in a study of treatment matching with persons who 
had a wide range of alcohol problem severity, AUDIT scores were compared with 
diagnostic data that reflected low, medium, and high degrees of alcohol dependence. 
AUDIT scores in the range of 8 -15 represented a medium level of alcohol problems. 
Whereas, scores of 16 and above represented a high level of alcohol problems (Miller, 
Zweben, DiClemente, & Rychtarik, 1992). On the basis of experience gained from the 
use of the AUDIT in this and other research, it is suggested that the following 
interpretation be given to AUDIT scores: Scores between 8 and 15 are most appropriate 
for simple advice focused on the reduction of hazardous drinking; Scores between 16 
and 19 suggest brief counseling and continued monitoring; and AUDIT scores of 20 or 
above clearly warrant further diagnostic evaluation for alcohol dependence (Babor, de la 
Fuente, Saunders, & Grant, 1992).
HCV Stigma Scale (modified) - Stigma, was measured using a modified version 
of the HIV Stigma Scale. The HCV Stigma Scale is a measure tailored for this study 
from the original version, the HIV Stigma Scale. This instrument measures stigma 
perceived by persons living with HIV in the U.S., and was developed based on the 
literature on stigma and psychosocial aspects of having HIV. The 40 items are centered
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on the experiences, feelings, and opinions about how persons living with HIV feel and 
how they are treated. The person living with HIV responds to these items using a four- 
point scale to indicate level of agreement or disagreement.
Psychometric analyses were performed and resulted in four factors emerging from 
exploratory factor analysis. Those four factors consist of: Personalized stigma,
Disclosure concerns, Negative self-image, and Concern with public attitudes toward 
people living with HIV. Construct validity was supported by relationships with related 
constructs: self-esteem, depression, social support, and social conflict. The ranges of the 
coefficient a  were between .90 and .93 for the four subscales and .96 for the 40-item 
instrument provided evidence of internal consistency reliability. The HIV Stigma Scale 
was reliable and valid with a large, diverse sample of persons living with HIV (Berger, 
Ferrans, & Lashley, 2001).
The scoring of the modified HIV Stigma Scale and subscales begins with 
participants answering items about some of the social and emotional aspects of having 
HCV. This first set of questions asks about some of the experiences, feelings, and 
opinions about how persons with HIV feel and how they are treated. Participants are 
asked to rate each item, and to circle each answer: Strongly disagree (SD), Disagree (D), 
Agree (A), or Strongly Agree (SA). Items are scored as follows; SD = 1; D = 2; A = 3; 
and SA = 4.
In order to control for response bias, two items (#8 and 21) have been worded in a 
positive direction. If a subject selects a response in between two options (e.g.: between 
SD and D), a numerical value midway between the two options would be used (e.g.: 1.5).
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After reverse scoring these two items, each scale or subscale’s score is calculated by 
simply summing up the raw values of the items belonging to that scale or subscale.
Subscale designations appear in small print in the far right margin of the 
instrument; it may be desirable to cover or delete those numbers before reproducing the 
instrument for administration to participants. Sixteen items belong to more than one 
subscale, reflecting the intercorrelations of the factors on which the subscales are based. 
The range of possible scores depends on the number of items in the scale. For the total 
HIV Stigma Scale, scores can range from 40 to 160 [1 x 40 items to 4 x 40 items]. For 
the personalized stigma subscale, scores can range from 18 to 72. For the disclosure 
subscale, scores can range from 10 to 40. For the negative self-image subscale, scores 
can range from 13 to 52. For the public attitudes subscale, scores can range from 20 to 
80 (Berger et al., 2001).
Demographic variables - Demographic characteristics and related clinical 
information collected included: gender, age, race, marital status, tribal affiliation, veteran 
status, level of education, HCV risk factor, type of HCV treatment, duration of HCV 
treatment.
DATA ANALYSIS PLAN
The Statistical Package for Social Sciences (SPSS) Version 20 was utilized for 
statistical data analysis. Prior to data analysis, each variable was examined using 
frequency distributions and visual representations. Once an analysis of the demographics 
of the study sample was completed (Hoskins & Mariano, 2004), the overall scale and 
subscale scores of the CES-D, AUDIT, HCV Stigma (modified) scales and measurement 
of the QOL PCS and MCS scores were assessed in the research study sample. An
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assessment and internal reliability of the subscales was measured using Cronbach a 
(McDowell, 2006). Chi-square tests for categorical, ANOVAs, t-test, and bivariate 
correlations for continuous variables were used in order to measure and describe the 
relationships between the variables (Creswell, 2009). A multivariate multiple regression 
analysis was utilized to examine which variables explain the greatest amount of variance 
in QOL. In predictive analyses based on probability theory, the independent variables 
cause variation in the value of the dependent variable (Mertler & Vannatta, 2002). The 
goal is to determine how accurately one can predict the value of an outcome (dependent) 
variable, QOL, based on the values of the predictor (independent) variables.
A diagnosis of HCV infection is often unexpected and can be devastating. There 
is a significant impact on the QOL among persons living with HCV infection. Not only 
do the clinical manifestations such as fatigue diminish functioning but also living with a 
chronic stigmatized illness with an uncertain future creates dilemmas around disclosure, 
accessing support, and sustaining self-esteem, employment, and relationships. In this 
research study, the focus is on identifying and describing the unmet health care needs and 
barriers to treatment was explored through the use of a descriptive study using a self­
administered survey comprised of the standardized measures of the SF-12v2, CES-D, 




The purpose of this study was to explore the relationship among depression, 
alcohol consumption, stigma, and quality of life among AI/ANs living with HCV. In this 
chapter, the sample is described, including their scores on the predictor variables of 
depression, alcohol consumption, stigma, and the outcome variable of quality of life.
This chapter concludes with the findings related to the specific research aims.
SAMPLE CHARACTERISTICS
A purposive sample of 101 AI/AN participants living with HCV was recruited 
from the Southwest region of the U.S. The sample characteristics, including patient 
demographics and health information/history, were collected utilizing a Personal Data 
Collection form designed for this study (Appendix L). Clinical data consisting of 
laboratory results were collected for participants from study Site 2 (n = 65) (Appendix 
M). Relevant demographic, health information/history, and clinical data of the study 
sample are reported in Tables 1,2, and 3. The sample was fairly evenly distributed by 
gender with slightly more males (54.5%, n = 55) than females (43.6%, n = 44); 2% self­
identified as transgender or lesbian (n = 2). The mean age was 50.56 years (SD = 8.773) 
ranging from 23 to 70 years of age. Marital status was approximately equally distributed 
among individuals who were divorced or separated (34.7%, n = 35), single or never 
married (32.7%, n = 33), married or partnered (27.7%, n = 28), with the exception of
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widows/ers who composed 5% of the sample (n = 5). Similarly, the sample was evenly 
divided among individuals who had a primary partner (49.5%, n = 50) and those who did 
not (49.5%, n = 50). Out of those who reported having a primary partner, 88.2% (n = 45) 
were partnered with someone of the opposite sex and 74.5% (n = 38) currently living 
with their primary partner.
The major Native / Tribal languages among the participants was Kumeyaay 
(Dieguefio) (13.9%, n = 14), Navajo (Din£) (12.9%, n — 13), and O’odham (14.9%, n = 
15). Approximately two-thirds (65.3%, n = 66) reported not residing on Al reservation or 
land. Education level was as follows: 1% (n = 1) had attended graduate or professional 
school; 5% (n = 5) had obtained a Bachelor’s degree; 34.7% (n = 35) had completed 
some college; 14.9% were High School graduates (n = 15); 19.8% (n = 20) had obtained 
a GED, 16.8% (n = 17) had completed some high school; 3% (n = 3) had obtained an 
Associate’s degree; and 5% (n = 5) had completed Elementary school. This sample also 
reported their occupational status as unable to work or unemployed (32.7%, n = 33), 
disabled (26.7%, n = 27), or working full-time (26.8%, n = 27), with the majority 
describing their present or most recent job or occupation in the crafts, trades, factory 
work, retail, or labor industry (57.4%, n = 58). Over one-third (38.6%, n = 39) reported 
an annual income of all members o f participants’ household in the range of $0 - $ 10,000.
The majority of the sample had not served in the U.S. Armed Forces (91.1%, n = 
92). There were only nine respondents who reported ever serving in the U.S. Armed 
Forces. There was a varied response regarding how easy it was to afford or access 
medical treatment for HCV. It ranged from very easy 20.8% (n = 21), to somewhat easy 
37.6% {n = 38), somewhat difficult 18.8% (n = 19), and very difficult 22.8% (n = 23).
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Approximately two-thirds reported having a type of health care coverage other than 
Indian Health Services. The type of health care coverage composed of either having 
Medicaid (33%, n = 37) as their health care provider or having No other coverage at all
(33.9%, n -  38). A summary of Sample Characteristics is presented in Tables 1 -4.
Table 1 Sample Characteristics
Variable N %
Age
2 3 -4 0 13 12.9
4 1 -5 0 34 33.7
51 -6 0 43 42.6






Single / Never Married 33 32.7
Married / Partnered 28 27.7
Divorced / Separated 35 34.7
Widowed 5 5.0
Primary Partner (husband, wife, significant other)
Yes 50 49.5
No 50 49.5
Don’t Know / Refuse 1 1.0
Primary Partner’s Gender
Same Sex 6 5.9
Opposite Sex 45 44.6




Table 2 Sample Characteristics
Variable N % %  of cases




Alaska Native 3 1.7 3.0
American Indian 96 55.8 95.0
Black / African American 3 1.7 3.0
Hispanic / Latino 14 8.1 13.9
Mexican / Mexican American 15 8.7 14.9
Native Hawaiian / Pacific Islander 1 0.6 1.0
White / Caucasian 35 20.3 34.7
Other 5 2.9 5.0
Total 172 100% 170.3%
Language
Native / Tribal 70 39.1 69.3
English 100 55.9 99.0
Spanish 9 5.0 8.9
Total 179 100% 122.2%
Education
Elementary 5 5.0
Some High School 17 16.8
High School graduate 15 14.9
GED 20 19.8
Some college 35 34.7
Associate’s degree 3 3.0
Bachelor’s degree 5 5.0
Some graduate school 1 1.0
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Unable to work / Unemployed 33 32.7
Disabled / Handicapped 27 26.7
Income (total annual household)
< 10,000 39 38.6
10,001-20,000 17 16.8
20,001 -  30,000 14 13.9
30,001 -40,000 9 8.9
40,001 -  50,000 11 10.9
50,001 -  100,000 5 5.0
> 100,001 3 3.0
Don’t Know / Refused 3 3.0
Afford/Access Medical Treatment for HCV
Very easy 21 20.8
Somewhat easy 38 37.6
Somewhat difficult 19 18.8
Very difficult 23 22.8
Job Category -  present or most recent job / occupation
Professional / Administrative 9 8.9
Clerical / Sales 11 10.9
Crafts / Trades / Labor 58 57.4
Healthcare / Technical 15 14.9
Hospitality / Service Industry 3 3.0
Military / Government 1 1.0





Table 4 Sample Characteristics — Native /  Tribal Language
Variable N %











Kumeyaay (Diegueflo) 14 14.0
Lakota 4 4.0
Luisefio 9 9.0
Luisefto- Cupeflo 5 5.0
Menominee 1 1.0
Miwok 1 1.0












The next section of the Personal Data Collection form focuses on the sample 
characteristics of health information and history. Over half of the participants, 50.9% (n
54
= 58) stated that they had not received treatment for HCV. Also reported, were those 
participants who received HCV injection plus oral medications (17.5%, n = 20), 
traditional or ceremonial healing (13.2%, n = 15), complementary and alternative 
medicine treatment (8.8%, n = 10). The primary reason for individuals to get tested for 
HCV based on the percentage of cases (79.2%, n = 80) was having risk factors, even 
though they were asymptomatic at the time of testing. The other significant reasons for 
getting tested were due to either blood donor screening or evaluation of elevated liver 
enzymes, 61.4% (n = 62) and 24.8% (n = 25), respectively. A summary of Sample 
Health Information/History and Clinical Characteristics is presented in Table 6. The 
HCV signs and/or symptoms reported most often experienced were fatigue (78.3%, n =
72), dark urine (62%, n = 57), and arthralgia (56.5%, n = 52).
Slightly more than half of the participants, (53.5%, n = 54) reported knowing that 
they were a contact of a person with confirmed or suspected acute or chronic HCV 
infection - (14.9%, n = 15) did not know. In the six months before symptom onset 
(regardless of gender / sexual preference), over half 52.5% (» = 53) and 51.5% (n = 52) 
responded as to having zero male or female sex partners. The number of participants 
who have ever been treated for a sexually transmitted disease or infection was 72.3% (n =
73). A summary of Frequency -  Treatment for Sexually Transmitted Diseases/
Infections is presented in Table 5.
Over 80% (86.1%, n = 87) reported ever using illicit or illegal drugs. Those who 
had ever used or shared a needle or syringe to inject drugs intravenously not prescribed 
by a health care worker was 62.4% (n = 63). Fifty-four (53.5%) had ever used or shared 
equipment to inject drugs intravenously not prescribed by a health care worker.
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Approximately two-thirds of participants (32.7%, n = 33) had been diagnosed with 
diabetes mellitus by a medical doctor; and o f those, 97% (« = 32) did not share their 
diabetic supplies.
Table 5 Frequency -  Treatment for Sexually Transmitted Diseases /  Infections
Sexually Transmitted Disease / Infection N %  of cases
Bacterial Vaginosis 4 5.5%
Chlamydia 21 28.8%
Gonorrhea 25 34.2%
HepB Virus 1 1.4%
HepC Virus 32 43.8%
Herpes, Genital 7 9.6%
HIV / AIDS 11 15.1%




Venereal Disease 5 6.8%
Pediculosis Pubic (crabs) 1 1.4%
Seventy-nine (78.2%) participants who reported not ever having an accidental 
stick or puncture with a needle or other object contaminated with blood. A majority of 
participants, 99% (« = 100), responded as never undergoing or receiving long-term 
kidney hemodialysis. Approximately 16% (15.8%, n = 16) had ever received blood or 
blood products by transfusion before July 1992; years received range between 1973 and 
1991. Those who responded as not ever having received any outpatient intravenous 
infusions and/or injections were 93.1% (n = 94).
Slightly over half (54.5%, n = 55) reported not ever and 15.8% (n = 16) did not 
know if they ever been in contact with a person’s blood who had hepatitis. Slightly less
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than 2/3rds (60.4%, n -  61) responded as not ever and 20.8% ( n -  21) did not know if 
they ever had been exposed to someone else’s blood who had hepatitis. The number of 
participants who were ever employed in a medical or dental field involving direct contact 
or exposure mucosally or to non-intact skin with human blood or infected needles was 
10.9% (n = 11) with frequent or infrequent exposures, 5 and 6, respectively. A large 
number, 94.1% {n = 95) stated they did not ever work as a public safety or emergency 
worker having direct contact or exposure mucosally or to non-intact skin with human 
blood or infected needles; 96% (n = 97) responded as not ever being a resident of a long­
term care facility.
In terms of treatment and law enforcement, 63.4% (n = 64) of participants 
responded as not ever being a resident o f an inpatient drug treatment program. Also, 
those who were not ever a resident of a halfway house were 72.3% (n = 73). The number 
of participants reported ever being incarcerated was 83.2% (n = 84). The length of 
incarceration categories and frequencies are: <30 days, 3 1 -1 8 0  days, 181 -  540 days, 
541 -  720 days, and >721 days, 42.9% (n = 36), 16.7% (n = 14), 10.7% (n = 9), 9.5% (n 
= 8), and 20.2% (n = 17), respectively. Those who have ever received a tattoo(s) or have 
any part of their body pierced (other than their ear) was 78.2% (n = 79) and 22.8% (n = 
23), respectively.
The following section pertains to transplant and blood risk, there were no 
participants, 100% (n = 101) who had ever been diagnosed and / or treated by a medical 
doctor for hemophilia. The majority, 98% (n = 99) had not ever received blood clotting 
factor concentrates produced before 1987. Those participants who ever received dental 
work / oral surgery or surgery (other than oral) prior to their HCV diagnosis was 76.2%
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(n = 77) and 57.4% (n = 58), respectively. There were no participants who had ever 
received a solid organ transplant before July 1992.
Table 6 Sample Health Information /  History and Clinical Characteristics
Variable N % of cases
Treatments received - HCV
No treatment 58 57.4%
HCV injection + oral medication 20 19.8%
Traditional or ceremonial healing 15 14.9%
Complementary and alternative treatment 10 9.9%
HCV injection only 8 7.9%
HCV oral medication only 2 2.0%
HCV surgery -  organ transplant 1 1.0%
Reasons for HCV testing
Screening -  asymptomatic, risk factors 80 79.2%
Blood / organ donor screening 62 61.4%
Elevated liver enzymes 25 24.8%
Follow-up testing for previous marker of viral hepatitis 9 8.9%
Screening -  symptomatic, no risk factors 8 7.9%
Symptoms of acute hepatitis 2 2.0%
Prenatal screening 2 2.0%
The final section will report the Clinical Data collected from study Site 2. The 
data collected from study Site 2(n  = 65), 64% of total study sample (n = 101) focuses on 
the clinical characteristics of laboratory and diagnostic results. The data collected was 
not complete due to the diagnostic tests being not done or tests not performed. There are 
specific laboratory tests performed in HCV disease screening and management. A 
summary of the Clinical Predictor Variable Descriptives is presented in Table 7.
HEPATITIS C
The hepatitis C antibody (anti-HCV) is the initial test in determining if HCV 
infection is present. A positive finding indicates the body’s response to HCV infection 
and the body is making antibodies in order to fight the infectious process. Sixty (92%) 
had a confirmed true positive for anti-HCV, which indicates infection with HCV in the 
past. This type of positive test result warrants additional confirmation testing to 
determine whether or not the anti-HCV is a true positive.
The hepatitis C recombinant immunoblot assay (RIBA) is the confirmation test 
for the hepatitis C antibody. A positive RIBA test result confirms the detection of a true 
positive anti-HCV, which suggests HCV infection in the past. More than half of the 
participants from Study site 2 (n = 40) had a positive RIBA test result showing past 
infection of HCV. Again, with a positive RIBA test, an HCV RNA viral load 
(quantitative) would need to be performed in order to detect the presence of HCV in the 
body.
The next test, HCV polymerase chain reaction (PCR), is a qualitative test utilized to 
confirm whether HCV is present. A positive test result confirms there is chronic HCV 
infection. More than 80% (n = 54) had HCV PCR positive results confirming chronic 
HCV infection, which is a more accurate test in detecting very low HCV levels versus the 
quantitative test method. In contrast, only eight participants had a negative HCV PCR 
test as a result from either successful response to HCV drug therapy or spontaneous 
clearing of HCV. An equivocal test results for one participant indicates there was some 
reactivity but not sufficient to be considered a positive HCV PCR finding.
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Table 7 Clinical Predictor Variable Descriptives










Type IB 4 (10.0)
Type 2B 5(12.5)
Type 3A 3 (7.5)
















Note: * = p <00\ , p -value is Pearson Chi-Square; § = No statistics are computed because
lab result is a constant.
Globally, HCV consists of six distinct genotypes and is further classified into 
many subtypes. These genotypes are considered to be the genetic structure of the virus 
and lay the groundwork for the standard of care and predicted response in HCV
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treatment. Genotyping is useful in disease management in terms o f medication regimen, 
dosing, and duration. In the U.S., genotypes 1,2, and 3 are most common. However, 
genotype 1 is most difficult to treat and accounts for 70-75% of all HCV infections. The 
data collected from study site 2 shows that 25 participant’s HCV genotyping were not 
done or tests were not performed and that antiviral treatment was not indicated. Whereas, 
67.5% (n = 27), 10.0% (n = 4), 12.5% (n = 5), 7.5% (n = 3), 2.5% (n = 1) tested as 
genotype 1 A, IB, 2B, 3A, and 4A/4C/4D, respectively.
HEPATITIS A
The hepatitis A virus (HAV) is considered to be highly contagious and the most 
prevalent type of hepatitis. It is an acute inflammatory condition of the liver with the 
majority of cases being acquired by ingestion of the virus, which is shed in the stool of 
infected persons, mostly fecal-oral transmission. A concern for those who are living with 
HCV is this distinct class of viral illness affecting the liver. Many of the HCV risk 
factors also pose risk for HAV infection, which require screening, testing, and 
prevention. The vaccine for HAV is recommended to all eligible persons and especially 
those with liver disease and HCV risk factors as a preventative measure according to 
CDC vaccination guidelines.
The confirmation of HAV by testing for Total anti-HAV is required to detect 
presence of any antibody against HAV and also indicate infection. Total anti-HAV 
appears early during the course of infection and remains detectable for lifetime. It also 
provides lifelong protection against HAV infection or disease. There was an equal 
distribution for those participants who tested positive for Total anti-HAV or tests not 
performed, (75.7%, n = 28). A positive interpretation results in either acute HAV or past
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HAV infection. A little over 21.6% (n = 8) tested negative for total anti-HAV and 2.7% 
(n = 1) resulted in a test result of equivocal. An equivocal result means that there is some 
reactivity, however, not enough to be positive or negative based on laboratory reporting 
criteria.
The IgM anti-HAV test is associated with active or recent infection with HAV. 
The presence of IgM antibodies is usually detected in the blood as early as two-weeks 
after being infected with HAV or when symptoms of HAV are present, and last for a few 
months after symptoms subside. A large proportion (n = 55) had negative IgM anti-HAV 
test results, indicating no active or recent infection with HAV.
HEPATITIS B
The HBsAg, Hepatitis B surface antigen, is a marker o f current infection. The 
presence of HBsAg may also indicate either acute or chronic HBV infection. In this 
sample, 55 participants tested negative for HBsAg and one tested positive, indicating 
current infection.
The total anti-HBc, antibody to Hepatitis B core antigen, is a nonspecific marker 
of acute, chronic, or resolved HBV infection. It appears at the onset of symptoms in 
acute Hepatitis B and persists for life. While is it not a marker of vaccine-induced 
immunity, it may be utilized in pre-vaccination testing to determine previous exposure to 
HBV infection. There were 19 participants that tested negative and 5 tested positive for 
total anti-HBc.
The IgM antibody to Hepatitis B core antigen is a test that identifies antigens, 
which is a substance on the surface of a virus that causes the immune system to recognize 
it and respond. An exposure to an antigen is viewed as foreign material and the body
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takes the necessary steps to neutralize the antigen by producing antibodies. Therefore, a 
positive IgM anti-HBc test result indicates recent infection with HBV. The presence of 
IgM anti-HBc also may indicate acute HBV infection. A large majority (n = 53) tested 
negative; (n = 1) tested positive; and (n = 11) did not have an IgM anti-HBc done or test 
was not performed.
Research Questions Findings
Aim #1: What is the level of depression, alcohol consumption, stigma, and quality
of life among a sample of AI/ANs living with HCV.
The use of descriptive statistics, means, standard deviations, and range were 
calculated in order to describe the levels of depression, alcohol use, stigma, and quality of 
life (PCS and PCS) in a sample of AI/ANs living with HCV (Table 8).
Table 8 Descriptive Variables Statistics
Variable M SD Cronbach’s a
CES-D 20.33 13.301 .920
AUDIT 14.10 10.005 .889
STIGMA 97.07 19.756 .942
Personalized 42.14 11.019 .94
Disclosure 26.21 5.328 .78
Negative Self Image 29.29 6.54 .80
Public Attitudes 49.51 11.016 .92
QOL -  PCS 41.32 11.075 .868
QOL-MCS 46.56 11.774 .879
Depression (CES-D)
The reliability coefficient for CES-D in this study a  = .92 is consistent with 
previously reported a ’s .85 to .90 (Radloff, 1977); .87 (Hodge & Kipnis, 1996); .88
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(Clark, Mahoney, Clark & Eriksen, 2002). The overall CES-D profile for this sample had 
a mean of 20.33 (SD = 13.301) and scores ranging from 0 to 50. Higher scores on the 
CES-D indicate higher levels of distress. Less than half of the sample (42.6%, n = 43) 
had scores greater than 21, which is indicative of possibility of major depression that may 
require further evaluation and treatment. A total o f 39 (38.6%) scored less than 15, 
showing no depressive symptomatology, and 19 (18.8%) scored between 15 and 21, 
indicating the presence of mild to moderate depression. A summary of Descriptive 
Statistics -  CES-D is presented in Table 9.
Table 9 Descriptive Statistics -  CES-D
CES-D scores N %
No depression (0 -14) 39 38.6
Mild to moderate depression (15-21) 19 18.8
Possibility of major depression (22 - 50) 43 42.6
Alcohol Use Disorders Identification Test (AUDIT)
The AUDIT score profile of this sample consisted of a mean of 5.23 (SD = 8.082) 
scores ranging from 0 to 40. Those surveyed scoring in the range of 0 -  7 (no hazardous 
drinking) was 76.2% (n — 77). A range of scores between 8 - 1 5  indicate advice to 
reduce hazardous drinking for 13.9% ( n -  14) of participants.
In contrast, 2.0% (n = 2) scored 17, which necessitates brief counseling and 
continued monitoring; 7.9% (n = 8) scored between 2 1 - 4 0  indicating need for further 
diagnostic evaluation for alcohol dependence. The reliability coefficient of the AUDIT 
in this study was .89 and is consistent with previous findings .86 (Barry & Fleming,
1993; Sinclair, McRee & Babor, 1992). A summary of the Descriptive Statistics -
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Patterns o f Alcohol Consumption is presented in Table 10.
Table 10 Descriptive Statistics -  Patterns o f  Alcohol Consumption
AUDIT scores N %
No hazardous drinking (0 -7) 77 76.2%
Advise to reduce hazardous drinking (8 -15) 14 13.9%
Brief counseling and continued monitoring (16 - 20) 2 2.0%
Further diagnostic evaluation for alcohol dependence (21 - 40) 8 7.9%
HCV STIGMA
The overall total stigma score for this sample consisted of a mean of 97.07 (SD = 
19.756) scores ranging from 54 to 145. The personalized subscale scores ranged from 18 
to 70 with a mean of 42.14 (SD = 11.019). The level of stigma was evenly distributed for 
both levels of stigma categories. The minimal to low stigma scores ranged from 18 to 40 
(46.5%, n = 47) and moderate to high stigma scores range from 41 to 64 (48.5%, n = 49). 
The personalized stigma addressed the perceptions or consequences of other people 
knowing that the participant is living with HCV, losing friendships, feeling that others are 
displaying avoidant behavior, or having regret in divulging to some people.
The reliability coefficient of Stigma in this study is .942 which is consistent with 
previous findings .96 (Berger, Ferrans & Lashley, 2001). The reliability coefficients for 
each of the subscales ranged from .79 to .92 in this study compared to the reliability 
coefficients for each of the subscales as reported by Berger, Ferrans & Lashley (2001) 
which range from .90 to .93. A summary of Stigma Subscale scores by Levels o f  Stigma 
is presented in Table 11.
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Table 11 Stigma Subscale scores by Levels o f  Stigma
HCV Stigma Sample
Scores
Minimal to Low Stigma 
(16 - 40)
Moderate to High Stigma 
(41 - 64)
Personalized 18 -7 0 46.5%, n = 47 48.5%, 77 = 49
Disclosure 13-38 97%, 77 = 98 77 = 0
Negative self-image 16 -4 7 91.1%, 77 = 92 8.9%, 77 = 9
Public attitudes 2 3 - 7 6 19.8%, 77 = 20 71.3%, 77 = 72
The disclosure subscale scores ranged from 13 to 38 with a mean of 26.21 (SD = 
5.328). The level of disclosure stigma by category for minimal to low stigma largely 
consisted of scores ranging from 17 to 38 (97%, n = 98). A majority perceived this level 
of stigma by having control of their personal health status or information, keeping their 
HCV status a secret, or worry that others who know of their HCV status would tell 
others.
The negative self-image subscale scores ranged from 16 to 47 with a mean of 
29.29 (SD = 6.540). Slightly more than 90% experienced a minimal to low level of 
perceived stigma relative to negative self-image which dealt with feeling unclean, not as 
good as others, or like a bad person because of HCV. The level of negative self-image 
stigma by category for minimal to low stigma consisted of scores ranging between 16 to 
39 (91.1%, n -  92), and moderate to high stigma with scores ranging between 41 to 47 
(8.9%, n = 9).
The public attitudes subscale scores ranged from 23 to 76 with a mean of 49.51 
(SD = 11.016). The level of public attitudes stigma by category for minimal to low 
stigma consisted of scores ranging between 23 to 40 (19.8%, n = 20), and moderate to 
high stigma with scores ranging between 41 to 64 (71.3%, n = 72). This revealed a
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moderate to high level of perceived stigma regarding the public’s attitudes and what most 
people think about a person with HCV or what most people with HCV can expect when 
others learn they have HCV. A summary of the Descriptive Statistics -  HCV Stigma is 
presented in Table 12.






Total Stigma Score 54 - 145 4 0 -1 6 0 97.07 19.756
Personalized subscale 1 8 - 7 0 1 8 -7 2 42.14 11.019
Disclosure subscale 1 3 -3 8 1 0 -4 0 26.21 5.328
Negative self-image subscale 1 6 -4 7 1 3 -5 2 29.29 6.54
Public attitudes subscale 2 3 - 7 6 20-80 49.51 11.016
Quality of Life (SF-12v2)
The outcome variable, QOL was measured using the SF-12v2 questionnaire, a 12- 
item instrument consisting of two subscales: physical component subscale (PCS) and 
mental component subscale (MCS). The PCS is an overall measure of physical health 
and a reflection of a person’s satisfaction with their perceived level of physical function, 
mobility and role limitations due to their health status. In contrast, the MCS is an overall 
measure of mental health impacted by depression, sense of well-being, and the ability to 
participate in social activities. The reliability coefficients for each of the subscales 
ranged from .868 (PCS) and .879 (MCS) in this study compared to the reliability 
coefficients for PCS and MCS as reported by Ware et al. (2002) which ranged from .89 
and .86, respectively.
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The overall range of sample scores for PCS is 20 -  63 with a mean of 41.32 (SD = 
11.075). Almost 3/4* (71.3%, n = 72) reported participant’s physical health being worse 
than the typical U.S. person. Less than a third 28.7% (n -  29) reported participant’s 
physical health better than the typical U.S. person. The range of scores for MCS is 21 — 
71 with a mean of 46.56 (SD = 11.774). Over half, 58.4% (n = 59) reported participant’s 
mental health is worse than the typical U.S. person; 41.6% (n = 42) reported mental 
health better than the typical U.S. person. A summary of Descriptive Statistics -  Quality 
o f  Life (SF-12v2) is presented in Table 13.
Table 13 Descriptive Statistics -  Quality o f  Life (SF-12v2)
Quality of Life (SF-I2v2) N %
Physical health better than typical US person 29 28.7
Physical health worse than typical US person 72 71.3
Mental health better than typical US person 42 41.6
Mental health worse than typical US person 59 58.4
Aim #2: What is the relationship among the variables o f age, gender, residing on an
AI/AN reservation, current partner status, depression, alcohol 
consumption, stigma, and quality of life (PCS, MCS) in a sample of 
AI/ANs living with HCV.
Chi-square tests for categorical variables, ANOVA or t-test for continuous 
variables by categorical variables, and correlations between continuous variables were 
used to examine bivariate relationships between participant characteristics and quality of 
life (PCS and MCS).
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Participant QOL - PCS
One-way ANOVA indicated a statistically significant relationship between PCS 
and gender (F = 4.8, p  = .03), and trending toward significance is the relationship 
between PCS and residence on AI reservation/land (F= 3.46, p  = .06). Correlational 
analysis indicated a statistically significant inverse relationship between PCS and CES-D 
score (r = -.438, p  = .000); trending toward significance is the inverse relationship 
between PCS and Stigma (r = -.183, p  = .06). A summary of the Correlation Matrix -  
Predictor Variables and QOL is presented in Table 12.
Participant QOL - MCS
Correlational analysis indicated a statistically significant positive relationship 
between MCS and Age (r = .205, p  = .04); statistically significant inverse relationship 
between MCS and CES-D score (r = -. 726, p  -  .000) and MCS and Stigma (r -  -.279, p  
= .005). Statistically significant inverse relationships were found between Age and CES- 
D (r = -.220, p  = .027); Age and Stigma (r = -.212, p  = .034); Age and AUDIT (r = - 
.243, p  = .01); and trending toward significance for having a current primary partner (r = 
.172,p = .08).
Residence on AI reservation/land was statistically significant inversely related 
with AUDIT (r = -.225, p  = .02) and approaching significance for having a current 
primary partner (r = .189,/? = .06). A statistically significant positive relationship was 
found between CES-D and AUDIT (r = .400, p  = .000); CES-D and Stigma (r = .485, p  
= . 000); AUDIT and Stigma approached a statistically significant positive relationship (r 
= .192, p  = .05). A summary of the Correlation Matrix -  Predictor Variables and QOL 
-  PCS & MCS is presented in Table 14.
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Table 14 Correlation Matrix -  Predictor Variables and QOL -  PCS & MCS
1 2 3 4 5 6 7 8 9
1 QOL - PCS 1.000
2 Gender .217* 1.000
3 Age (in years) -.078 -.074 1.000
4 Resides on AI Reservation .184 .081 .090 1.000
5 QOL - MCS .165 .144 .205* .081 1.000
6 Current Primary Partner .012 .000 .172 .189 .100 1.000
7 CES-D -.438** -.158 -.220* -.130 -.726** -.088 1.000
8 AUDIT -.124 .046 -.243* -.225* -.148 -.027 .400** 1.000
9 STIGMA
00I -.175 -.212* -.075 -.279** -.023 .485** .192* 1.000
* Correlation significant at 0.05 (2-tailed) 
** Correlation significant at 0.01 (2-tailed)
Aim #3: Identify factors that explain the greatest amount of variance in the quality
of life in a sample of AI/ANs living with HCV.
Simultaneous multiple regression analyses were conducted to examine the amount 
of variance in the DV. A multiple regression approach is appropriate whenever a 
quantitative variable is to be examined in relationship to predictor variables (Cohen, 
Cohen, West & Aiken, 2003). This standard multiple regression strategy was suitable 
because all independent variables are viewed as having equal importance, there were no 
apriori hypotheses, and regression diagnostic procedures did not detect problems with 
multicollinearity among the predictor variables.
Collinearity
Collinearity describes a situation when a high correlation is detected between two 
or more predictor variables. When high correlations are detected, they can pose problems 
when attempting to draw inferences about the relative contribution of each predictor 
variable to the success of the model. In the use of simultaneous multiple regression
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method, the researcher specifies the set of predictor variables that comprises the model 
(Mertler & Vannatta, 2013).
When testing for assumptions, the predictors are not highly correlated. This is 
supported by Pearson correlations not being > 0.9, Variance Inflation Factor (VIF) <10, 
and tolerance > 0.2. A formal method for determining the presence of multicollinearity is 
the VIF. The VIF measures how much variance of estimated regression coefficients are 
inflated when compared to having uncorrelated predictors (Hair, Black, Babin, & 
Anderson, 2010). Tolerance was used as an indicator of multicollinearity and estimated 
and calculated by regressing the predictor variables onto the remaining variables included 
in the multiple regression analysis. There were no outliers and the outcome was normally 
distributed. Tolerance statistics exceed 0.1 for all variables indicating multicollinearity is 
not evident. A summary of collinearity statistics -  PCS and MCS is presented in Table 
15 and 17, respectively.
Quality o f Life 
Participant QOL - PCS
Regression results indicate the overall model significantly predicts participants’ quality of 
life: Participant Quality of Life - Physical Health, R2= .252, R2adj~ .195, F  (7,92) =
4.429,p  = .000. This model accounts for 25% of the variance in QOL-PCS. A summary 
of the regression coefficients indicated only one (CES-D) of the seven variables 
significantly contributed to the model (Table 16).
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Age (in years) .880 1.137
Reside on AI Reservation/Land .909 1.100




Table 16 Coefficients for Model Variables - PCS
Independent Variables B B t P
Gender 2.00 .097 1.045 .299
Age (in years) -.208 -.166 -1.727 .087
Reside on AI Reservation/Land 3.252 .141 1.495 .138
Current Primary Partner -.579 -.026 -.283 .778
CES-D -.396 -.480 -4.297 .000
AUDIT .054 .040 .380 .705
STIGMA .017 .030 .285 .776
Multiple R = .502 R2 adj = . 195
R2 = .252 F  (7,92) = 4.42, p  = .000
Participant QOL - MCS
Regression results indicate the overall model significantly predicts participants’ 
quality of life: Participant Quality of Life - Mental Health, R2 = .569, R2̂  -  .536, F  (7,
92) = 17.352,/? = .000. This model accounts for 56% of the variance in QOL-MCS. A 
summary of the regression coefficients in Table 16 indicated two (CES-D and AUDIT) of
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the seven variables significantly contributed to the model. A summary of the Coefficients 
for Model Variables - MCS is presented in Table 18.




Age (in years) .880 1.137
Reside on AI Reservation/Land .909 1.100




Table 18 Coefficients for Model Variables -M CS
Independent Variables B 0 * P
Gender 1.148 .052 .736 .463
Age (in years) .122 .091 1.242 .217
Reside on AI Reservation/Land .160 .006 .090 .928
Current Primary Partner .413 .018 .248 .805
CES-D -.729 -.824 -9.714 .000
AUDIT .257 .177 2.239 .028
STIGMA .067 .113 1.424 .158
Multiple R = .754 R2 adj = .536




This chapter will provide a brief summary of the research study, relate the 
findings to prior research, and suggest possible directions for future studies. This 
descriptive correlational study was conducted to examine factors associated with quality 
of life among AI/AN adults living with HCV. This chapter concludes with the findings 
related to specific research aims that may have important implications for hepatitis 
education, treatment, AI/AN health policy, and practice improvements.
HCV is a silent epidemic that is taking a toll on Indian Country and; generating 
considerable concern and raising important public health challenges including long-term 
health, financial, and social consequences. Quality of life, and not just health, has 
emerged as an important issue for AI/ANs living with HCV. However, research on 
quality of life in AI/ANs with HCV remains limited and is virtually nonexistent. 
Information from this study may help nurses develop interventions that facilitate effective 
coping strategies and help to advance the science to improve QOL among AI/ANs living 
with HCV.
In the study reported here, depression scores indicated that 38.6% had no 
depressive symptomatology; 18.8% reported the presence of mild to moderate 
depression, and 42.6%, had scores suggesting possibility of major depression. An 
analysis by gender indicated a difference in depressive symptomatology where half of all
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women in this sample (n = 22) had a score indicating the possibility of having major 
depression. Given the dearth of inquiry on depression and AI/ANs living with HCV, 
these findings are congruent in many ways with the overall AI/AN women specific 
mental health challenges and opportunities (Duran et al, 2004).
Not surprisingly, the changes HCV brings can lead many with the condition to 
feel anxious, irritable, and even depressed. Among AI/AN people, there is a wide range 
of beliefs about illness, healing, and health. For the AI/AN population, the overall 
concept of mental illness and beliefs as to why and how it develops contain many diverse 
meanings and interpretations. Frequently there is an experiential disconnect between 
physical illness and psychological distress (Hodge, Limb, & Cross, 2009). They are 
often not adequately distinguished and AI/ANs may express emotional distress in ways 
not consistent with standard diagnostic categories. This could explain the range of 
responses overall and between gender regarding depression as measured by the CES-D.
There is a growing body of evidence suggesting that persons with HCV have a 
higher prevalence of mental health illness, and persons with mental health illness have 
four to nine times the prevalence of HCV (Rifai & Rosenstein, 2005, U.S. DHHS, 1999 
& 2001). Depression is common, and therefore, it is important to find support through 
support groups, trusted friends and family, or online communities. Interacting with 
others living with HCV, persons can learn about the challenges other people are facing, 
find strength and impart coping strategies with each another. The pervasiveness of 
stigma that’s associated with seeking mental health care keeps AI/ANs from seeking and 
ultimately receiving the necessary treatment.
It is essential for nursing and other health care providers to recognize the
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seriousness of co-occurring depression in persons infected with HCV. Overall, the CES- 
D provides a reliable and valid measure to screen for depressive symptoms in this 
population. However, discourse bringing increased attention and focus on depression 
within AI/AN communities is imperative to provide effective care and HCV disease 
management.
The level of alcohol consumption measured by the AUDIT indicated for this 
sample there was no association or implication o f harmful or hazardous drinking. An 
analysis between gender and AUDIT showed non- significant relationship. The 
relationship between residing on an AI reservation / land and pattern of alcohol 
consumption was significant which is concerning in conjunction with prior findings of 
depression significantly more common among alcoholics than non-alcoholics 
(Numgerger, Foroud, Flury, Meyer & Wiegand, 2002; Norton, Redd & Bryan, 2002).
There is empirical evidence for co-morbidity of mood and anxiety disorders 
among AI/AN women with any lifetime substance use disorders. In this sample these co­
morbidity rates among AI/AN women were higher than rates in non-AI/AN women 
reported in other studies (Duran et al, 2004). The level of consumption warrants further 
analysis in relation to HCV to determine safe levels of alcohol consumption, given there 
was a large group of respondents scoring below the cut-off score o f not having harmful or 
hazardous drinking pattern of alcohol.
Stigma produces many challenges for AI/ANs living with HCV and their social 
networks, communities, and place in society. Despite the development and support by 
legislation, policy, and guidelines to protect and serve persons living with HCV, evidence 
continues to report stigma within their communities and even health care delivery
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systems. There was moderate to high level of personalized stigma reported as 
consequences of family or community discovering they are living with HCV, losing 
friendships, sensing others displaying avoidant behavior, or expressing regret in 
divulging their HCV status to others. Due to the size of some AI/AN reservations, social 
networks and kinships tend to magnify their place in those communities. Notably, there 
are few health care delivery systems and thus it is commonplace to exchange and share 
local/tribal community news. This close knit community of AI/ANs creates apprehension 
for disclosure, which could lead to friends and family discovering their HCV status and 
negatively impact their social support.
A moderate to high level of stigma regarding public attitudes also dealt with 
issues surrounding what most people think about a person with HCV or what most people 
with HCV can expect when others learn they have HCV. The attitudes of health care 
providers were thought to have been detrimental for those seeking medical treatment or 
access of health care services, this has the potential to cause damaging effects, isolation, 
depression, and increased disease burden and coping with their HCV status (Zickmund, 
Ho, Masuda, Ippolito, & LaBrecque, 2003). The majority of participants noted living 
with HCV lead to being stigmatized because of the whole association of HCV with 
injecting drug use or engagement with high-risk behavior. This misinformation leads to 
assumptions that all persons living with HCV have a history of injection drug use in spite 
of the many ways HCV can be acquired (Butt, 2008). In many ways, much like society 
in general, AI/AN communities also lack compassion and understanding about the 
injective drug using population.
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A minimal to low level of stigma related to disclosure centered around having 
control of one’s personal health status or information, keeping their HCV status 
confidential, or being concerned that others who knew of their HCV status would 
disclose to others. Some participants resolved to avoid disclosing their HCV status to 
prevent any sort of discrimination or added stigma even from certain health or social 
services worker, family, and friends. Disclosure was also seen by many to result in being 
judged or condemned by their own family members, tribal community, and healthcare 
setting. A segment of stigma that was not explored in this study and merits further 
examination is how disclosure affects access to housing, employment, and access public 
resources.
A minimal to low level of stigma related to negative self-image concentrate on 
factors like feeling unclean, not as good as others, or like a bad person due of their HCV 
status. Beyond the physical symptoms of HCV, the condition can take its toll on the 
mental or feeling aspects of life quality. There were shared emotional responses where 
participants often expressed feelings of shame and stigma from when they first heard 
their diagnoses of HCV and after years of living with their illness, to today. Often, 
participants conveyed their reluctance in revealing their diagnosis with others, which 
further lead to feelings of isolation and loneliness.
The area of research in the concept of stigma has been overlooked within AI/AN 
populations. And, more specifically within the context of living with HCV. The overall 
relationship between HCV and stigma requires further study and deconstruction in order 
to gain an appreciation and fully understand the current state of stigma within an 
indigenous worldview. This allows for positive systematic changes in the provision of
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AI/AN healthcare, policy, and practice that can serve as a guide and provide quality care 
to AI/ANs living with HCV, bringing increased HCV knowledge and awareness to 
AI/AN communities, their leaders, and stakeholders.
The results are consistent when comparing participants with the general 
population norm; more than half of the study sample scored below general population 
norms on both the PCS, MCS, and all eight health domain subscales (Younossi, 2001). 
This is an indication that the participants have worse physical and mental health than the 
typical U.S. person. Alarmingly, when taking into account gender differences, there was 
a significantly larger percent of female scores below the general population norm than 
males for both PCS and MCS.
Again many of these factors need to be further explored to draw inferences on 
specific health domains that impact quality o f life. It can be postulated that many of the 
barriers demographically could be factors that impact quality of life. Many of the 
potential demographics may include: type of health care coverage, HCV treatment 
disparities, HCV symptoms, Education level, Income, Access to care, and HCV risk 
factors, to name a few. However, other factors not included in this study could explain 
quality of life and include cognitive fimction and co-morbidities, (Cordoba et al, 2003, 
Hussain et al, 2001).
Correlation and simultaneous multiple regression analyses were conducted to 
determine how well age, gender, residing on AI reservation / land, marital status, current 
partner, depression, alcohol consumption, and stigma predicted quality of life. For the 
QOL-PCS outcome, the simultaneous multiple regression model with seven predictors 
produced R2 = .252, indicating these predictors account for approximately 25% of the
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variability in QOL-PCS. Depression was the only independent variable to contribute to 
the model. In contrast for the QOL-MCS outcome, the simultaneous multiple regression 
model with all seven predictors produced R = .569, indicating these predictors account 
for approximately 57.0% of the variability in QOL-MCS. The regression analysis 
indicated the model significantly predicts QOL-MCS.
Limitations of the Study
The results of the analyses must be viewed in the context of their limitations. Due 
to the small/unique sample available for the study, results may not be generalizable 
beyond the specific population from which the sample was drawn. Data was collected 
via a survey comprised of four measures: Personal Data, QOL, CES-D, AUDIT, and 
STIGMA. It is possible that some questions were not culturally equivalent for AI/ANs 
populations.
All measures was administered by the PI, thus participants could be influenced by 
social desirability and human memory during self-report, which can consequently 
influence data accurateness. Respondent burden could be a limitation to the data 
accurateness, the length of the survey may have influenced responses, for instance several 
participants appeared to be anxious about time even though the PI provided the 
opportunity to complete the questionnaire before, during or after their appointment, or at 
a later time of the convenience.
In addition, cross-sectional data allows for analysis at one point in time and 
longitudinal data are needed both to describe the course of QOL and determine the 
impact of depressive symptoms plus the co-occurring conditions on the health of the
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participants. Nonetheless, these findings are important because typically studies still do 
not examine the co-occurrence of psychosocial issues particularly in AI/AN with HCV.
This study was the first to tailor the STIGMA scale for use with AI/AN with HCV 
and, it demonstrated acceptable content validity, further testing of the STIGMA scale is 
needed to ensure reliability and validity among HCV populations.
Implications and Recommendations 
Nursing Practice Implications
HCV is a silent disease and considered a public health threat. Through robust 
research and advancing the science is critical in order to improve and develop care 
models targeting HCV, AI/ANs populations are underrepresented in national studies 
(Lead, 2012). The American Association for the Study of Liver Diseases (AALSD) also 
argue what is necessary to effectively manage liver disease is advancing clinical 
guidelines as new treatment options are on the horizon and constantly evolving. There is 
a mandate to remain vigilant in prevention thus advocacy is a key strategies.
The current study was completed using a descriptive cross-sectional survey 
design. Additional research is needed and could be implemented using a longitudinal 
design to determine if changes over time become perceptible. Further investigation can 
use qualitative methods to build the theoretical foundation based on AI worldview and 
mixed methods to guide practice through research.
Nurses, as advocates and change agents, can facilitate the improvement in QOL, 
reducing the burden of disease, and closing the gaps in healthcare inequality. In terms of 
the issues of depression, investments can be made in providing evaluation of activities 
already in use among other health care models to establish practice-based evidence rather
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than expecting evidence-based practices not developed or tested in AI/AN communities 
to work effectively.
The discourse among health care disciples about screening and prevention on 
alcohol use and improving HCV treatment services for eligible participants that have low 
risk or abstinence from alcohol use is needed. A key strategy is to decrease stigma and 
bring increased awareness and structural, systematic changes with the involvement o f key 
community advisory stakeholders to educate their tribal community, health delivery 
system, and government. Stigma has an impact. Through education and dialogue, 
increased knowledge will reduce and eliminate the burden of stigma.
The advent of new treatment strategies aims to achieve higher efficacy with 
shorter duration, easier administration, and client adherence. The role for nurses is: to 
provide continued HCV medication management and support during treatment, to ensure 
adherence, and include interdisciplinary team members. HCV medication side effects are 
common; patients and family members need support and encouragement throughout 
treatment as it affects their quality of life. Given the wide range and potential seriousness 
of adverse reactions, clients need close and regular monitoring from nurses at regular 
intervals. Adherence and support during treatment is undoubtedly one of the key factors 
for success in achieving a sustained viral response, which is an outcome that is a state of 
being cured.
Nursing Education Implications
The role of nursing is essential in helping patients, families, and communities 
become active participants in healthcare. While the traditional methods of nursing 
education for patients has fallen short in terms of targeting chronic disease and yield
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positive behavior change, the use of motivational interviewing has been shown to an 
effective method in facilitation, adoption, and implementation to improve treatment 
outcomes for patients and their support systems (Bishop and Jackson, 2013). An element 
of cultural competence must also be an emphasis as there are many variations of AI/AN 
culture that is dynamic, shared, symbolic, learned, and integrated (Dunn, 2002). This 
transformational educational approach will align nursing educators and healthcare 
systems initiative as exemplary accountable care organizations (ACOs).
An expansion on cultural competence would be to explore another area that may 
impact health outcomes. Nurses can involve lay community health workers (CHWs) to 
provide education, support, and outreach based on the needs through community-based 
interdisciplinary intervention (Tyler, Nyamathi, Stein, Koniak-Griffin, Hodge, &
Gelberg, 2013). The utilization of CHWs in tribal communities are frontline public 
health workers and considered by elders and lay community as trusted members and have 
a close understanding of their community.
This relationship and collaboration with nursing enables CHWs to serve as 
intermediaries between health care organizations and AI/AN communities to facilitate 
access to services and improve quality and cultural competence health care service 
delivery. To further strengthen communities, nursing educators can engage AI/AN 
community advisory boards (CAB) to effectively target those areas of need and develop 
partnerships focusing on HCV Awareness, Prevention, Testing, Risk reduction, and HCV 
Treatment and Support (American Academy of Nursing, 2013). This innovative 
approach will allow nurses to evaluate innovative health care models and, in turn, can
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bring it back to CABs and provide cultural competent educational models of 
sustainability and community participatory research (Wame, 2006).
Depression, alcohol consumption, and stigma are all serious problems related on 
some level to the QOL of AI/ANs living with HCV. Nurses have a responsibility to meet 
the need of this population, however, this study, like previous studies indicate that HCV 
knowledge is poor among some health care professionals. It is imperative for the QOL of 
AI/ANs living with HCV that nurses continue to explore this ‘silent killer’ using both 
qualitative and quantitative methods. It is through research and evidence that is culturally 
based with interventions grounded on AI/AN worldviews that is critical in educating 
others about effective treatment.
Nursing Policy Implications
The nation’s recent healthcare climate change of improving access to care and the 
U.S. government’s commitment in providing preventive care and services is paramount 
and timely. This is considered to be the most significant and far reaching health care 
reform since the establishment of Medicaid and Medicare. The overarching goal of the 
Patient Protection and Affordable Care Act (ACA) has the potential to benefit those 
living with HCV by improving access to needed health care services and treatment; and 
diagnosing viral hepatitis earlier and preventing new HCV infections.
The AC A mirrors many local government’s HCV Strategic goals to improve 
access to care and treatment, strengthen community health centers, end discrimination 
against pre-existing conditions (stigma), and prioritize reduction of health disparities. 
While the expansion of healthcare coverage is currently underway, barriers still exist, as 
some states have yet to agree on expanding Medicaid services to their eligible citizens.
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Also, those who are undocumented citizens will not be covered by the ACA. Other 
challenges include: legal immigrants will continue to be ineligible for Medicaid for the 
first 5 years in the U.S.; may not be affordable for some citizens; and requires continued 
funding from Congress. The continued realization of ACA will require innovative 
nursing and healthcare leadership and visionary providers, advocates, government, and 
stakeholders the ensure ACA sustainability through partnerships.
Nursing Research Implications
A future consideration is to include qualitative study emphasizing illness 
experience of AI/AN persons living with HCV. This would provide an AI/AN 
perspective and worldview into the psychosocial consequences of living with HCV. It 
would also be vital to examine illness narratives and find relationships from depression 
and stigma results. This would impart another level of valuable information needed to 
gain a better understanding in how persons explain the burden of depression or stigma, 
successful coping, and the unique features associated with living with depression, stigma, 
and HCV infection.
The need for future studies is evident. Further examination of depression, alcohol 
consumption, stigma, and quality of life in different communities of AI/ANs living with 
HCV is needed. Notably, larger and longitudinal studies are needed to determine 
potential cause and effect relationships among depression, alcohol consumption, stigma, 
and quality of life prior to designing and testing interventions aimed at increasing health 
and quality of life in this population. In adequately addressing the health concerns 
identified through this study, further research and expansion of other AI/AN HCV 
population groups needs to focus on: data quality and accuracy to address under-
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representation of AI/ANs in population health data, the lack o f access to health care 
services for AI/ANs in both rural and urban settings, lack of incorporation of traditional 
health care practices, the efficacy of health promotion and disease prevention activities, 
and the lack of health insurance coverage among AI/ANs.
The limitations of the mental health care system along with the systematic and 
cultural barriers to care that impede health care services utilization and access for 
AI/ANs. There is an urgent call for future research to address gaps in public health 
knowledge about mental health care among AI/ANs, especially research focused on 
pathways and barriers to care, financial infrastructure for AI/AN mental health and 
testing interventions. Future research for depression may include and focus on: 
interventions to build community support for mental health care; theoretical models for 
contextualizing care within communities and systems of care; and development of brief 
interventions embedded in community settings, or delivered by telephone. Overall, 
additional research is necessary to elucidate the complexities of HCV infection that 
impact AI/AN populations.
Conclusion
The purpose of this study was to examine the relationship between depression, 
alcohol consumption, stigma, and quality of life in the AI/AN populations. A review of 
the literature reveals a need for additional research to examine the how AI/ANs are living 
with HCV and compare the effects of their HCV status, stigma, alcohol consumption, and 
depression on QOL dimensions. Findings indicate depression is significantly related to 
QOL, with stigma approaching significance for AI/AN with HCV infection.
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The information regarding HCV infection in the U.S. is improving but there are 
still many opportunities for improvement and narrowing the gaps in our knowledge.
These developments are necessary to enable better prevention, screening, testing, 
treatment, disease management of HCV, and to guide research, planning for those with 
hepatitis C disease. The government, health care delivery systems, and stakeholders have 
put in place, underpinned by the Affordable Care Act, a comprehensive response to 
address the health care issues for the uninsured and underinsured.
The advent of new therapies, innovative research, infrastructure, and health policy 
there are yet many challenges and opportunities in raising the health status of those 
persons living with HCV. The paradigm of care aligns itself very much with the 
philosophy of nursing. Through the continued efforts of nursing scholarship and 
leadership and recent introduction of unified national health structure for our health 
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Tuesday. August 2D, 2011
University of f>*n nipxju 
Institutional Review board 
Alin: Jane  M. Geopges. PhD. RN 
5908 Alcala Park 
SanDiogo, CA 92110
Re: Letter of Support 
Dear Or. Georges:
I, a s  the CEO of Indian Health pound ; fac-Voor CMO* Dr. Daniel.C^at, arid M».-: 
Ry<i ell “Dale'' Todicheeney rece n tty met to discuss ::he’ researcti. prefect. "Qualityof; ' 
Life among Hepatitls C Amierican Indians in Run?! Southern. C^forrtfci The litdian' 
Health Council. Inc. Administratibn and its Institution Reyi^vBbarti’apflreciates'. . 
that Dale will t>e submitting a 'proposal in OTtlo/lorhirh (pcbhducia rosearch atii'dy: 
as part of his Dorr.qr uf Philosophy in Horsing dissertatidiVdt theUniversity of.San - ■ 
Dieso Hahn Scnbdi of Nurcing-ar.d Health Sclehoe, ‘ ■ • -I
We unde-Tstand that art individual's leeliugs and'thepxper ience of their H^patftis C ' - 
LIness ind jsive of copfpg processes iriHzoti cahjHi’s  KxeJy vru»paUy«iy. rffeqt (h«pr. 
quality of fife, th e  infrrrualiun (earned fronrpie rfeseqrpti wiII provide. YaSuablci _' 
information thalmay benefit this targeted pwpniatiori'ar.G q j.' community trffougtv- 
Improved H^paiilis C education, community awanan«S$'. pa ten t services, ciirilcal 
mandgdiYtent, s r.d.pcogram develop merit. We are pleased toprcvide Dala a letter •. 
of support In this; valuab e research endeavor. He may utilize the Ircion Health .. 
CourwiL Inc, facility ghd its Service arpa a*  a  recrUtenertl sRe. A workspscefcf: IT 
private patient interviews and a data dolJectiohsitc will be acconirrrodaterl ■
It would be an fidnor and a privilege to be w faesirence n supporting this research 
project. S hould you have any further questions or concerns, please do'rSt h'esiia le . 
tp. contact us 'at <7B0j 74t^14W. Thar* you. ,iv  . :
Respectfully youri;.
S ire ie  Majal Mcunuiey 
ChtefExecttivo Officer 
Ad ihbi is (ration OebitrtTtarit
':  par.iei 
-•-Chiof Hadi^TOifffsier . 
•• /internal Modfcine/f^odiatficG
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I )nc oral C andidate
I k i i i n S s l u r l  u l ' N u r s i n g  ani l  h e u l l . "  S c d ' C O
Cnivcre.Tv or San Ldis'pu
S'W.H A lcala Park
Sail D ieg u . C iilll'o -n io  9 ? I 10
Dear Mr. T od ich .'cney ,
. he adm in istra tion  o f  th e  Phoenix  S erv ice  Mint has re s  -ewed th e  p ro p o sa l to r 
vour quality  im provem ent pro ject, en titled  "Q u alits  o f  L ife  A m urip H ep a titis  C A f . 'A W ”
1 . he p iop o scd  pip icvl co n cen ts  an issu e  in a iield  c o n v x ie n  w ith  ’he m ission  and
priorities o f  the Phoenix Indmu M od eal C enter
2 I he researcher has g iv en  a - s.m m eo :h v  IR R  appro val ’.si,I bo nought and  m at
appropriate re sc arch  and p rivuc; p rac tices vs. i lr be I oil ow ed
1 i he resea rch er has iden tified  a P iM C  em p lo y ee  w .io  can  p rov ide lia ison  betw een
the researcher and the CTO .
This protect has the endorsem ent o f  ihe  P hoenix  Serv ice L nit ad tu .iiis tia tio n  to  seek 
tltndtnp and approval for research  b> the Phoenix  A rea Instill.iiortul R ev iew  Rtir.rd. All 
research m ust have h e n  Serv ice I.Hit h iK lcrsem ent and phoen ix  A rea  1RB approval prior 
to initial ion o r  public:, '.ion
W hile )t is custom ary  for the 1RB to send c o p ie s  o r approvals to  the P hoenix  S erv ice  
Mint, it is the duty o f  the resea rch er to assu re  that tits' S erv ice  U nit h a s  received  
no tifica tion  o lu p p ro v a ' He lore co m m en c in g  resea rch  or pT H ication .
Jehu M olina. M D. JD
(. ittef fcxec. ttve CUticer 
Phoenix Indian M edical C enter
u  R esearch b d e
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Clinic 6* Main 
O ffice
SOIOOGolsh Road 
Valley Center, CA 
92082 
Mali: P.O. Box 406 
Paurru Valley, CA 
92061 
(760) 749 1410 
Fax (760) 749-1S64
S an ta  Ysabel
Satellite Clinic 
P.O. Box 10 




Indian H ea l th  Council^ Inc.
March 28,2012
Re: Quality of Life among Hepatitis C American Indians in Rural 
Southern California
Dear Mr. Todicheeney,
Your project referenced above was reviewed and approved in 
accordance with the Indian Health Council, Inc. (IHC) IRB assurance 
and federal requirements pertaining to human subjects protections 
within the Code of Federal Regulations (45 CFR 46; 21 CFR 50). In 
addition, your brochure and flyer for the project were also approved. 
This review is valid through March 28, 2013, and applies to the 
conditions and procedures described in your protocol. Please notify the 
IHC IRB Committee if your status as an USD student changes while 
conducting this research.
Your study recruitment will take place through IHC, but you must 
confirm those procedures with IHC staff prior to initiation of your study. 
If study recruitment takes place outside of IHC, you must confirm with 
that institution that you have permission to conduct the study prior to 
initiation of any study activities.
Your Consent Form must display the USD IRB stamp of approval along 
with the IHC IRB stamp of approval and must be read aloud to 
participants.
This approval, based on the degree of risk, is for 365 days from the 
date of IHC IRB review and approval unless otherwise stated in this 
letter. The regulations require that continuing review be conducted on 
or before the 1-year anniversary date of the IHC IRB approval, even 
thought the research activity may not begin until some time after the 
IRB has given approval.
Date of IRB review and approval: March 28,2012
If you have any questions, please contact me: dmorton@ucsd.edu.
Deborah J. Morton, PhD, MA, Chair
Indian Health Council, Inc., Institutional Review Board
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DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Phoenix Area Indian Health Service 
Two Renaissance Square 
40 North Central, Suite 600 
Phoenix, Arizona 85004-4424
December 7, 2012
Rydell Todicheeney, MSN, MBA/HCM 
Doctoral Candidate
Hahn School of Nursing and Health Science 
University of San Diego 
5998 Alcala Park 
San Diego, CA 92110
Dear Mr. Todicheeney,
Thank you for submitting the protocol ““Quality of Life among Southwest American Indian/Alaska 
Natives Living with Hepatitis C In Urban Dwellings.' It has been assigned the protocol number PXR 
12.18. Please utilize this designation in any documentation and in all communication to the Phoenix Area 
IHS IRB related to this study.
Upon review by the Phoenix Area IHS IRB your protocol was ‘Approved with recommendations.” Work 
may begin once the IRB receives a response of needed information. The Phoenix IHS IRB had the 
following recommendations that require a response:
Specific to the questionnaire to be used, the reviewers would like a response to the following:
* Are validated questionnaires being used?
o QOL and HCV stigma scale -  provide clarification on their statistical reliability/validity 
o  PI stated the HCV stigma scale was an ‘adapted* instrument. If it was revised from another 
scale, what or how was it adjusted to ‘fit’ the study? -  making an adjustment to an 
established instrument requires some effort and documentation related to reliability and 
validity -  how was the validity of the ‘adapted* instrument demonstrated?
Upon receipt of the response to the recommendations by the Phoenix Area IRB, the research may begin. 
Your study is approved tor one year, through December 2, 2013.
Please be aware that any substantive changes in research activities may not be initiated without prior 
review and approval by the Phoenix Area IHS IRB. Federal regulation requires that any unanticipated 
problems involving risks to participants or others, or serious harm involving participants, be promptly 
reported to the IRB tor immediate review. If findings for this research are to be used in any papers tor 
publication, abstracts, oral or other presentations, this must be submitted to the Phoenix Area IHS IRB 
before such activity is undertaken.
Please submit a  Status Report and Renewal Application 30 days prior to the expiration date of this 
approval, November 2, 2013. The Status Report and Renewal Application form, along with additional 
information is available at www.ihs.oov/MedicalProorams/Research/index.cfm Go to Human Subject 
Protection IRB then Forms and Other Resources.
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DEPARTMENT O F HEALTH & HUMAN SERVICES Public Health Service
Phoenix Area Indian Health Service 
Two Renaissance Square 
40 North Central, Suite 600 
Phoenix, Arizona 85004-4424
January 28, 2013
Rydell Todicheeney, MSN, MBA/HCM 
Doctoral Candidate
Hahn School of Nursing and Health Science 
University of San Diego 
5998 Alcala Park 
San Diego, CA 92110
Dear Mr. Todicheeney,
Thank you lor submitting a response, per the IRB's request, for protocol PXR 12.18 -“Quality of Ufa 
among Southwest American Indian/Alaska Natives Living with Hepatitis C in Urban Dwellings '
Upon review by the Phoenix Area IHS IRB, your protocol was approved *as is’, and your research can 
begin. Your study is approved for one year, through December 2,2013.
Please be aware that any substantive changes in research activities may not be initiated without prior 
review and approval by the Phoenix Area IHS IRB. Federal regulation requires that any unanticipated 
problems involving risks to participants or others, or serious harm involving participants, be promptly 
reported to the IRB for immediate review. If findings for this research are to be used in any papers for 
publication, abstracts, oral or other presentations, this must be submitted to the Phoenix Area IHS IRB 
before such activity is undertaken.
Please submit a Status Report and Renewal Application 30 days prior to the expiration date of this 
approval, November 2, 2013. The Status Report and Renewal Application form, along with additional 
information is available at www.ihs.oov/MedicalProarams/Research/index.cfm Go to Human Subject 
Protection IRB then Forms and Other Resources.
On behalf of the IRB, thank you, and we wish you success with your research. If I may be of further 
assistance please contact me.
Sincerely,
Cynthia Claus, PhD, MPH 
Chair, Phoenix Area Institutional Review Board 
Director, Office of Health Programs 
Phoenix Area Indian Health Service
Appendix H
120
Invitation L etter fo r S tudy Partic ipation
19 March 2012
Dear Patient of Indian Health Council, Inc.:
This Invitation Letter for Study Participation has received support from 
Indian Health Council, Inc. on behalf of Dale Todicheeney, a Navajo nurse 
who served our community and is a University of San Diego doctoral 
student. You are being invited to participate in a research study that Dale is 
conducting for the purpose of learning more about patients living with the 
Hepatitis C Virus.
For participating in this study, you will receive $25 Cash or a $25 
Target Gift card. While Dr. Calac and his staff have mailed this letter to 
IHC patients who might be interested in a study like this, Dr. Calac or 
IHC is not sponsoring or funding this study. Nothing about your care at 
IHC or anything about your medical care/social services will change if you 
decide not to participate.
Your participation in this study about Hepatitis C is important and 
completely voluntary. If you are interested in participating, you will 
spend at least 60 minutes to complete the survey interview. You will have 
an opportunity to sit down with Dale at a private location, most likely at 
IHC, that is convenient for you and feel your privacy will be protected.
I hope you will be interested in participating and should you have any 
questions, please call Dale Todicheeney at 602-315-1315 or email him at 
dtodicheeney@gmail.com. Thank you.
Respectfully yours,
Dale Todicheeney, PhD(c), MBA/HCM, RN, PHN, ACNS-BC 
Doctoral Student
Hahn School of Nursing and Health Science 
University of San Diego
KF.F.P THIS FOR YOI R RECORDS
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Appendix I
Invitation L e tte r fo r S tudy Partic ipation
14 August 2012
Dear P1MC Patient:
This Invitation Letter for Study Participation has received support from 
Phoenix Area IHS on behalf of Dale Todicheeney, a Navajo nurse in our 
community and University of San Diego doctoral student. You are being 
invited to participate in a research study that Dale is conducting for the 
purpose of learning more about patients living with the Hepatitis C Virus.
For participating in this study, you will receive $25 Cash or a $25 
Target Gift card. While PIMC has provided you this letter and have 
expressed interest in participating in this study, PIMC is not sponsoring 
or funding this study. Nothing about your care at PIMC or anything 
about your medical care/social services will change if you decide not to 
participate.
Your participation in this study about Hepatitis C is important and 
completely voluntary. If you are interested in participating, you will 
spend at least 60 minutes with Dale to complete the survey interview. You 
will have an opportunity to sit down with Dale at a private location, most 
likely at PIMC, that is convenient and feel your privacy will be protected.
I hope you will be interested in participating and should you have any 
questions, please call Dale Todicheeney at 602-315-1315 or email him at 
dtodicheeney@gmail.com. Thank you.
Respectfully yours,
Dale Todicheeney, PhD(c), MSN, MBA/HCM, RN, PHN, ACNS-BC 
Doctoral Student
Hahn School of Nursing and Health Science 
University of San Diego
KF.EP THIS FOR \ O l R R l ( ORDS
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ID Code # _____________  Today’s  Date:__________/ 2012/2013
University o f San Diego 
Institutional Review Board
Research Participant Consent Form
For the research study entitled:
Quality o f Life Among Hepatitis C American Indian/Alaska Natives in Rural Southern California
I. Purpose of the research study
Dale Todicheeney. a student from the University of San Diego (USD) is conducting a study to find out 
more about Hepatitis C virus (HCV) among American Indian/Alaska Natives (AI/ANs). You have been 
invited because you are: living with HCV, AI/AN,utilizing Indian Health Council, Inc. (IHC) services.
II. What you will be asked to do
If you agree to be in this study, personal health information pertaining to your HCV diagnosis will be 
included in this study. This study involves questionnaires to better understand how you are living with 
HCV. The interview will last 60 minutes.
III. Foreseeable risks or discomforts
You will not be identified with your responses. No one but Dale will know how you answered these 
questions. Dale is responsible for managing the data and certified in confidentiality procedures. 
Sometimes when people are asked to think about their feelings, they may feel sad  or anxious. If 
you would like to talk to som eone about your feelings at any time, you may call:
Indian Health Council, Inc. - Human Services Department at 760-749-1410 or 
San Diego Mental Health Hotline at 1-800-479-3339
IV. Benefits and risks
Participation may involve a slight risk of loss of confidentiality, as none of the data gathered is highly 
sensitive. There may be no direct benefit to you; however, an indirect benefit is to know you are 
helping your community and health professionals to better understand how AI/ANs are living with HCV.
V. Confidentiality
Any information provided will remain confidential and be locked in a file and/or password-protected 
computer for a minimum of five years. All data collected will be coded with a number and your real 
name will not be used. The results of this study will only be presentedinaggregate form.
VI. Compensation
You will receive a $25 Target Gift card or $25 Cash for participating, even if you do not com plete 
the session .
VII. Voluntary Nature of this Research
Your participation Is entirely voluntary. You may refuse to answer any question or withdraw at any 
time. Deciding not to participate or not answering any of the questions will have no effect on any 
benefits you’re entitled to, like your health care, or employment. You can withdraw from this study at 
any time without penalty.
VIII. Contact Information
Dale has explained this study to me and answered my questions. The participant will be told if any 
important new information is found during the course of this study that may affect willingness to 
continue. You may contact Dale at (602) 315-1316 or the USD Institutional Review Board at (619) 260- 
4653 for more information about your rights as a participant, or to report research-related problems. 
Agreement: I have read and understand this form, and consent to the research it describes to 
me. I have received a copy of this consent form for my records.
Print Name I Signature of Participant Dale
Rydell ‘Dale’ Todicheeney. PhDfci. RNI___________________________________________________
Signature of Study Inveetigator Date
KF.F.P TIIIS FOR YOl R RF C ORDS
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Appendix K
Institutional Review Board 
Indian Health Council, Inc.
50100 Golsh Road 
Valley Center, CA 92082  
(760) 749-1410 
(760) 749-1564 (FAX)
PROJECTAL SUBJECTS BILL OF RIGHTS
The faculty and staff of the University of San Diego and Indian Health Council, Inc. wish you to know: 
Any person who is requested to consent to participate as a  subject in a research study involving a 
medical project, or who is requested to consent on behalf of another, has the right to:
1. Be informed of the nature and purpose of the project.
2. Be given an explanation of the procedure to be followed in a research project, and any drug or 
device to be used.
3. Be given a description of any attendant discomforts and risks reasonably to be expected from 
the project.
4. Be given an explanation of any benefits to the participant reasonably to be expected from the 
project, if applicable.
5. Be given a disclosure of any appropriate alternative procedures, drugs, or devices that might be 
advantageous to the participant, and their relative risks and benefits.
6. Be informed of the avenues of medical treatment, if any, available to the participant after the 
project if complications should arise.
7. Be given an opportunity to ask any questions concerning the project or the procedures 
involved.
8. Be instructed that consent to participate in the research project may be withdrawn at any time, 
and the participant may discontinue participation in the research project without prejudice.
9. Be given a copy of a signed and dated written consent form when one is required.
10. Be given the opportunity to decide to consent or not to consent to a project without the 
intervention of any element of force, fraud, deceit, duress, coercion, or undue influence on the 
participant's decision.
If you have questions regarding the research project. Dale Todicheeney, PhD(c), RN or the Research 
Study's Interview Supervisor, Cynthia D. Connelly, PhD, RN, FAAN will be glad to answer them. You 
may seek information from the Indian Health Council, Inc. Institutional Review Board -  established for 
the protection of volunteers in research projects -  by calling or by writing to the above address.
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  
Based on th e  results o f this research project, w e  m ay conduct future stu d ies. There Is no 
obligation to  participate in a future study  if you participate in th e  p resen t study.
P lease indicate how ever, if you agree for us to  con tact you in th e  future abou t possib le  
participation in any future stud ies.
May we contact you in the future about additional research? □  Yes Q  No 
If you checked yes, please provide your contact information (address, email, telephone):
KEEP T HIS FOR VO l R RECORDS
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ID Code # _____________  Today’s  Date:  _________2013
University of San Diego 
Institutional Review Board
Research Participant Consent Form
For the research study entitled:
Quality of Life among Southw est American indian/Alaska Natives 
Living with Hepatitis C In Urban Dwellings
i. Purpose of the research study
Dale Todicheeney, a student from the University of San Diego (USD) is conducting a study to find out 
more about Hepatitis C virus (HCV) among Southwest American Indian/Alaska Natives (AI/ANs). You 
have been invited because you are: living with HCV, AI/AN, and utilizing Phoenix Indian Medical Center 
(PIMC) healthcare services.
li. What vou will be asked to do
If you agree to be in this study, personal health information pertaining to your HCV diagnosis will be 
included in this study. This study involves questionnaires to better understand how you are living with 
HCV. The interview will last 60 minutes.
III. Foreseeable risks or discomforts
You will not be identified with your responses. No one but Dale will know how you answered these 
questions. Dale is responsible for managing the data and certified in confidentiality procedures. 
Som etim es when people are asked to think about their feelings, they may feel sad  or anxious. If 
you would like to talk to som eone about your feelings at any time, you may call:
Arizona Crisis Hotline at 1*866-205-5229
IV. Benefits and risks
Participation may involve a slight risk of loss of confidentiality, as none of the data gathered is highly 
sensitive. There may be no direct benefit to you; however, an indirect benefit is to know you are 
helping your community and health professionals to better understand how AI/ANs are living with HCV.
V. Confidentiality
Any information provided will remain confidential and be locked in a file and/or password-protected 
computer for a minimum of five years. All data collected will be coded with a number and your real 
name will not be used. The results of this study will only be presented in aggregate form.
VI. Compensation
You will receive a $25 Target Gift card or $25 Cash for participating, even if you do not com plete 
the session .
Vli. Voluntary Nature of this Research
Your participation is entirely voluntary. You may refuse to answer any question or withdraw at any 
time. Nothing about your care at PIMC or anything about your medical care/social services will change 
if you decide not to participate or answer any of the questions. You can withdraw from this study at 
any time without penalty.
Vli I. Contact Information
Dale has explained this study to me and answered my questions. The participant will be told if any 
important new information is found during the course of this study that may affect willingness to 
continue. You may contact Dale at (602) 315-1315 or the USD Institutional Review Board at (619) 260- 
4553 for more information about your rights as a participant, or to report research-related problems. 
Agreement: I have read and understand this form, and consent to the research it d escribes to  
me. I have received a copy of this con sen t form for my records.
Print Name I Signature of Participant Data
Rydell ■Date* Todicheeney. PtiDtcL RN I___________________________________________________
Signature of Study Investigator Date
KFf'.P THIS FOR > O i R R K O R D S
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PROJECTAL SUBJECT'S BILL OF RIGHTS
The faculty and staff of the University of San Diego and Phoenix Area IHS /  PIMC wish you to know: 
Any person who is requested to consent to participate as a subject in a research study involving a 
medical project, or who is requested to consent on behalf of another, has the right to:
1. Be informed of the nature and purpose of the project,
2. Be given an explanation of the procedure to be followed in a research project, and any drug or 
device to be used,
3. Be given a description of any attendant discomforts and risks reasonably to be expected from 
the project,
4. Be given an explanation of any benefits to the participant reasonably to be expected from the 
project, if applicable,
5. Be given a disclosure of any appropriate alternative procedures, drugs, or devices that might be 
advantageous to the participant, and their relative risks and benefits,
6. Be informed of the avenues of medical treatment, if any, available to the participant after the 
project, if complications should arise,
7. Be given an opportunity to ask any questions concerning the project or the procedures 
involved,
8. Be instructed that consent to participate in the research project may be withdrawn at any time, 
and the participant may discontinue participation in the research project without prejudice,
9. Be given a copy of a signed and dated written consent form when one is required, and
10. Be given the opportunity to decide to consent or not to consent to a project without the 
intervention of any element of force, fraud, deceit, duress, coercion, or undue influence on the 
participant's decision.
If you have questions regarding the research project, Dale Todicheeney, PhD(c), RN or the Research 
Study's Interview Supervisor, Cynthia D. Connelly, PhD, RN, FAAN will be glad to answer them. You 
may seek information from the Phoenix Area IHS - Institutional Review Board -  established for the 
protection of volunteers in research projects -  by calling (602) 364-5189 or writing to: Two 
Renaissance Square, 40 North Central Avenue, Suite 600, Phoenix, Arizona 85004. 
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Based on th e  results o f  th is research project, w e  m ay conduct future stu d ies. There is  no 
obligation to  participate in a  future stud y if you participate in th e  p resen t study.
Please Indicate how ever, if you agree  for u s to  con tact you in th e  future abou t possib le  
participation in any future stu d ies.
May we contact you in the future about additional research? □  Yes 0  No
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Institutional Review Board 
Indian Health Council, Inc.
50100 Golsh Road 
Valley Center, CA 92082 
(760) 749-1410  
(760) 749-1564 (FAX)
HCV Research Study Participant Incentive
For your voluntary participation in this HCV Research Study, you may choose one 
o f the following incentives. Please check the box indicating which incentive you 
would like to receive:




BF 0U 253679 k  
F6 _  i
BF0U2S3679A
Print Name / Signature of Participant Date
Rvdell ‘Pale* Todichecnav. PhPicl. RN /___________________________________________________




University o f San Diego 
Institutional Review Board
Today's Date:. 2013
Research Participant Incentive Form
For your voluntary participation in this HCV Research Study, you may choose one 
of the following incentives. Please check the box indicating which incentive you 
would like to receive:




\  tub r a n w  wmm\ QTAMKHftG*.8F 0U 2 5 3 6 7 9  A F6 _  i
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Print Name / Signature of Participant Date
Rvdell ‘Dale’ Todicheeney. PhDtci. RN /___________________________________________________
Signature of Study Investigator Date
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Instructions: This questionnaire contains 20 statem ents people might make about how they feel. 
P lea se  do not write your nam e on  th is form. P lease read each statem ent carefully and pick 
the best response that best indicates how often  you  fe lt that w ay during th e  p a st w eek. For 
each  item, circle your answ er: Then circle the number below the response you have picked.
1. I was bothered by things that usually don’t bother me
2. I did not feel like eating; appetite was poor
3. I felt that I could not shake off the blues, even with help 
from my family or friends
4. I felt that I was just as good as other people
5. I had trouble keeping my mind on what I was doing
6. I felt depressed
7 . 1 felt that everything I did was an effort
8 .1 fen hopeful about the future
9. I thought my life had been a failure
10. I fen fearful
11. My sleep was restless
12. I was happy
1 3 .1 talked less than usual
14. I felt lonely
15. People were unfriendly
16. I enjoyed life
17. I had crying spells
18. Ifensad
19. I fMt that people disliked me














































MUeofthe moderate amount ahneotattof





















Thank you for taking the tim e to  
complete the CES-D Scale Questionnaire!
i
Center for Epidemiological Studies Depression Scale Questionnaire (CES-D)
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Appendix R
ID Code #  _______________________   Today’s  Date:_
Alcohol Use Disorders Identification Test (AUDIT)
Script: Now I'm going to ask 10 questions about Alcohol Use and have made a 'response card'
with answer choices to help you select the best response
Instructions: Alcohol use can affect on e’s  health and interfere with certain medications & 
treatments. It’s important that I ask som e questions about alcohol use. Please do your best 
to answer each question honestly. To help you answer correctly, I have listed the standard drink 
serving size on the next page. For each of the following questions, please mark a ■  In the box that
b — t  d w c r i b n  vour answer. Please do not write vour name on this form
Monthly 
Nm t  o f  lees
M i m a
monSi
a s  Swim 
a w e
4 or i ro n
1 How often do you have a drink containing alcohol?
S k i p  t o  Q u e s t i o n a 9 a n d  10 I t  a n s e r e r  f o r  9 1 a  N E V E R
□  . □  . □  a □  a □  r
1 or 2 3 or 4 S orS 7,S ,o rS IS or m an
2 How many standard drinks containing alcohol do 
you have on a typical day when drinking?
□  . □  , □  a □  a □  r
N w r





3 How often do you have six  or more drinks on one □  . □  . □  a □  a □  o
Occasi0n?s*ip t o  Q u e s t i o n *  9 4 10 I f  T o ta l  S c o r e  f o r  i  2*3*0
4 During the past year, how often have you found 
that you were not able to stop drinking once you
□  . □  . □  a □  a C L
had started?
5 During the past year, how often have you failed to 
do what was normally expected of you because of
□  . □  , □  a □  a □  a
drinking?
6 During the past year, how often have you needed 
a drink in the morning to get yourself going after a
□  . □  , □  a □  , □  a
heavy drinking session?
7 During the past year, how often have you had a 
feeling of guilt or remorse after drinking?
□  . □  , □  a □  a □  a
8 During the past year, have you been unable to 
remember what happened the night before
□  . □  , □  a □  a □  a
because you had been drinking?
NO





f s a r
9 Have you or someone else been Injured as a 
result of your drinking?
□  . □  a □  i
10 Has a relative or friend, doctor or other health □ ,  Q 2
worker been concerned about your drinking or 
suggested  you cut down?
Total Score:_____________
Please, stop here!
This concludes th is section . Thank you for taking th e  tim e to  answ er th e  Alcohol
U se survey!
Adapted from The Alcohol Use Disorders identification Test (AUDIT), GuifeHnes for Use in Primary Care by the World Health Organization.
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Today’s  Date:_________
Alcohol Use Disorders Identification Test (AUDIT)
Rating your score
0 - 7: You're at low risk for problems caused by drinking alcohol.
8-15: You could be at risk for problems caused by drinking alcohol.
Making changes in your drinking habits can help lower your risk. 
Above 16: Scores above 16 could mean drinking alcohol is causing problems 
in your life.
Talk to your health care provider about these questions and your 
score. He or she will be able to work with you to help you cut down or 
stop drinking, and discuss any concerns or questions you may have.




12 ounces of beer or wine cooler 
1.5 ounces of 80 proof liquor 
5 ounces of wine
4 ounces of brandy, liqueur or aperitif
Thank you, 
for taking the time to complete 
the AUDIT Screening Tool!
2




HCV Stigma Scale -  (modified)
Instructions: This survey asks about some o f the social and emotional aspects o f having HCV. Please do 
your best to answer each question. Some questions may look like others, but each one is different. If you 
are unsure about how to answer a question, please give the best answer you can. For most of the questions, 
just circle the letters that go with your answer. There are no right or wrong answers.
Feel free to write in comments as you go through the questions. Please do not write your name on this 
form. This first set of questions asks about some of your experiences, feelings, and opinions as to how
people with HCV feel and how they are treated. For each item, circle your answer: Strongly Disagree 
(SD), Disagree (D), Agree (A), or Strongly Agree (SA).
1. In many areas of my life, no one knows that I have HCV.................................













2 .1 feel guilty because I have HCV.......................................................................... SD D A SA
3. People's attitudes about HCV make me feel worse about myself..................... SD D A SA
4. Telling someone I have HCV is risky................................................................. SD D A SA
5. People with HCV lose their jobs when their employers find out...................... SD D A SA
6 .1 work hard to keep my HCV a secret................................................................. SD D A SA
7 .1 feel I am not as good a person as others because I have HCV........................ SD D A SA
8 .1 never feel ashamed of having HCV.................................................................. SD D A SA
9. People with HCV are treated like outcasts.......................................................... SD D A SA
10. Most people believe that a person who has HCV is dirty................................ SD D A SA
11. It is easier to avoid new friendships than worry about telling someone that I SD D A SA
have HCV............................................................................................................
12. Having HCV makes me feel unclean................................................................ SD D A SA
13. Since learning I have HCV, I feel set apart and isolated from the rest o f the SD D A SA
14. Most people think that a person with HCV is disgusting............................. SD D A SA
15. Having HCV makes me feel that I'm a bad person.......................................... SD D A SA
Please, continue to next page
1
C Barbara Berger 1996 (Berger's HIV Stigma Scale modified with permission)
133
Today’s Date:
HCV Stigma Scale -  (modified)






16. Most people with HCV are rejected when others find out............................ SD D A SA
17.1 am very careful who I tell that I have HCV................................................. SD D A SA
18. Some people who know I have HCV have grown more distant................... SD D A SA
19. Since learning I have HCV, 1 worry about people discriminating against me SD D A SA
20. Most people are uncomfortable around someone with HCV........................ SD D A SA
21.1 never feel the need to hide the fact that I have HCV................................. SD D A SA
2 2 .1 worry that people may judge me when they learn I have HCV................. SD D A SA
23. Having HCV in my body is disgusting to me................................................ SD D A SA
Instructions: Manv of the items in this next section assume that vou have told other people that vou have 
HCV, or that others know. This may not be true for you. If the item refers to something that has not 
actually happened to you, please imagine yourself in that situation.
For each item, circle your answer: Strongly Disagree (SD), Disagree (D), Agree (A), or Strongly 
Agree (SA) based on how you think you would feel or how you think others would react to you.
S tn aU r a m a * ;  
Dfaagn* M u g m  A g m  A |n t
(80) (B) (A) <*A)
24.1 have been hurt by how people reacted to learning I have HCV................. SD D A SA
2 5.1 worry that people who know I have HCV will tell others.......................... SD D A SA
2 6.1 regret having told some people that I have HCV........................................ SD D A SA
27. As a rule, telling others that I have HCV has been a mistake....................... SD D A SA
28. Some people avoid touching me once they know I have HCV..................... SD D A SA
29. People I care about stopped calling after learning I have HCV SD D A SA
Please, continue to next page
2
© Baitara Berger 1996 (Berger's HIV Stigma Scale modified with permission)
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Today’s Date:
HCV Stigma Scale -  (modified)
For each item, circle your answer: Strongly Disagree (SD), Disagree (D), Agree (A), or Strongly 
Agree (SA) based on how you think you would feel or how you think others would react to you.
»»«■* SMartr
**«urn <m (A)
30. People have told me that getting HCV is what I deserve for how I lived my SD D A SA
life
31. Some people close to me are afraid others will reject them if  it becomes SD D A SA
known that I have HCV
32. People don't want me around their children once they know I have HCV SD D A SA
33. People have physically backed away from me when they learn I have HCV SD D A SA
34. Some people act as though it's my fault I have HCV SD D A SA
35.1 have stopped socializing with some people because of their reactions to SD D A SA
my having HCV
36.1 have lost friends by telling them I have HCV SD D A SA
37.1 have told people close to me to keep the fact that I have HCV a secret SD D A SA
38. People who know I have HCV tend to ignore my good points SD D A SA
39. People seem afraid of me once they learn 1 have HCV SD D A SA
40. When people learn you have HCV, they look for flaws in your character SD D A SA
Please, stop here!
Thank you, 
for taking the time to 
complete the HCV Stigma survey!
3
$  Barbara Berger 1996 (Berger’s HIV Stigma Scale modified with permission)
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Appendix T
ID Code # ___________________________  Today’s  Date: _/  2012 / 2013
Personal Data Collection
Script Thank you for agreeing to participate. I am going to limit (ha amount of time I spend on 
each question. If there is a question that you are unsure about or want more information on, we 
can discuss it at the conclusion of our session. I have provided RESPONSE CARDS to alow you 
to answer the questions.
Instructions: Please respond to the following questions, in order to better understand you and the 
impact your life experience and health history. Your responses will remain confidential so  please 
do your best to answer each question to the best of your ability.
KEY: The answ er choice “DK /  R e f  m eans Don't Know or Refused to answer
PATIENT DEMOGRAPHICS:
1. W hat is your G ender?
□  Female (1) □  Male (2) Q  If Other, please specify :____________(3)
2. W hat is your A ge?
___________________ Age in years □  DK / Ref (9)
3. W hat is your R ace / E thnicity? (Check all that apply) Y es No DK/Ref
3a. Alaska Native 1 2 9
3b. American Indian 1 2 9
3c. Asian 1 2 9
3d. Black or African American 1 2 9
3e. Hispanic or Latino 1 2 9
3f. Mexican or Mexican American 1 2 9
3g. Native Hawaiian /  Pacific islander 1 2 9
3h. White or Caucasian 1 2 9
3i. If Other. Dlease specify: 1 2 9
4. Which L anguage do you u se  most often?
□  My native /  tribal language:__________________________________ (1)
□  English (2)
□  Spanish (3)
□  If Other, please specify:_____________________________________ (4)
□  D K /R ef (9)
Please, continue to next pagel
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ID C o d e # Today’s  Data: I2012 / 2013
Personal Data Collection
5. Do you currently Reside I Live on American Indian reservation / land?
□  Yes (1) □  No (2) □  DK / Ref (9)
6. W hat is your current Marital Status? (Circle one)
□  Single /  Never married (1)
□  Married /  Partnered (2)
□  Divorced / Separated (3)
□  Widowed (4)
7. Do you currently have a  Primary Partner? A primary partner is someone with whom you 
love more than anyone else and feel a  unique commitment?
(If no, Skip question #8 and 9)
8. Is your Primary Partner som eone of the S am e sex, Opposite sex, or Both?
□  Sam e sex  (1) O  Opposite sex  (2) □  Both sex es (3) Q  DK /  Ref (9)
9. Do you currently Live with your husband, wife, primary partner, or significant other?
10. W hat is the Highest Level of formal education you com pleted or the highest degree you 
have received?
□  Never attended school (1)
G G rades 1 through 8 (Elementary) (2)
□  G rades 9 through 11 (Som e high school) (3)
□  Grade 12 (High school graduate) (4)
□  GED (5)
□  Som e college, no degree (6)
□  AA degree (7)
□  BA, BS degree (8)
□  Som e graduate or professional school (9)
G Graduate or professional degree (10) Specify d e g re e :______________________
G Yes (1) Q No (2) Q  D K /R ef (9)
G  Yes (1) Q  No (2) G DK / Ref (9)
Please, continue to next page!
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ID Code # _  Today’s  Date:__________/ 2012 / 2013
Personal Data Collection
11. What is your Occupational status?
□  Full-time outside the home (1)
□  Full-time in the home (2)
□  Part-time outside the home (3)
□  Student (4)
□  Retired (5)
□  Volunteer (6)
□  Unable to work / Unemployed (7)
G Disabled / Handicapped (8)
12. Which of the following Categories best describes vour present or most recent job or 
occupation?
□  Professional / Administrative (1)
G Clerical, Administrative Support, Sales or Marketing (2)
Q  Crafts, Trades, Factory Work, Retail Sales, or Labor (3)
Q  Military (4)
Q  Casino (5)
G  If Other, please specify:_________________________________________ (6)
G  D K /R ef(9)
13. Which category best describes your Total Yearly Income of ALL members of your 
household?
□  $ 0 - $ 10,000 (1)
Q  $10,001 to $20,000 (2)
Q  $20,001 to $30,000 (3)
Q  $30,001 to $40,000 (4)
G  $40,001 to $50,000 (5)
G  $50,001 to $75,000 (6)
Q  $75,001 to $100,000 (7)
Q  $100,001 to $150,000 (8)
G  Greater than $150,000 (10)
G  D K /R ef(9)
Please, continue to next pagel
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ID Code # _____________  Today’s  Date:__________12012 / 2013
Personal Data Collection
14. Have you ever served in the U.S. Armed Forces? Active duty includes serving in the U.S. 
Armed Forces as well a s  activation from the Reserves or National Guard.
□  Yes, on active duty in the p ast but not now (1)
□  Yes, now on active duty (2)
□  No, never on active duty except for initial/basic training (3)
□  No, never served in the U.S. Armed Forces (4)
(If Never Served, Skip question #15)
15. In which branch or branches did you serve on active duty? (Check all that apply)
O A rm y (1)
□  Navy (2)
□  Air Force (3)
□  Marine Corps (4)
□  Coast Guard (5)
□  Other (e.g., Public Health Service, Environmental Services Administration, 
National Oceanic and Atmospheric Administration, U.S. Merchant Marine) (6)
16. How easy is it for you to Afford (access) medical treatment for Hepatitis C?
□  Very easy (1)
□  Somewhat easy (2)
□  Somewhat difficult (3)
□  Very difficult (4)
17. This DOES NOT include Indian Health Service, IHS or tribal clinics or doctors where 
uninsured patients are charged according to their income. Do you have any type of health 
care coverage other than Indian Health Service? (check all that apply)
□  VA (Dept, of Veterans Affairs, CHAMPUS, CHAMPVA, TRICARE (Military) (1)
□  County Services (2)
□  Arizona Health Care Cost Containment System (Medicaid) (3)
□  Medicare, including Medigap supplement (4)
□  Out of pocket by you or your family (copayment) (5)
□  Private insurance purchased directly or by a family member, through a union, or 
from a current or former employer (6)
□  No other coverage (7)
□  If Other source, please specify:____________________________ (8)
□  DK/Ref (9)
Please, continue to next page!
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ID Code # ______________  T oday’* D a te :__________ / 2 0 1 2 /2 0 1 3
Personal Data Collection
18. W hat T reatm ents have you received  for Hepatitis C ? P lease check all that apply
□  American Indian Traditional Healing /  C erem onial Practices (1)
18a. What kind(s)?______________________________________
18b. When w as the most trea tm en t?______________________
18c. For how lo n g ?_____________________________________
G  C om plem entary and A lternative Medicine therapy (2)
For MMnpt*: acupuncture, healing touch. Reiki, yoga, biofeedback, hypnosis, meditation, 
chiropractic, and massage
18d. What kind(s)?  _____________________________
18e. When w as the most trea tm en t?__________________________________
18f. For how lo n g ?__________________________________________________
□  C om bined HCV Injection / Medication therapy (3)
18g. What kind(s)?__________________________________________________
18h. When w as the most trea tm en t?__________________________________
181. For how long?__________________________________________________
□  HCV Injection therapy only i.e.. Interferon (4)
18J. W hat k ind(s)?___________________________________________________
18k. When w as the most trea tm en t?__________________________________
181. For how long?__________________________________________________
□  HCV M edication therapy only i.e., Ribavirin, Telaprevir, Boceprevir (5)
18m. W hat kind(s)?_________________________________________________
18n. When w as the most trea tm en t?__________________________________
18o. For how long?__________________________________________________
□  Surgery / Organ T ran sp lan t (6)
18p. What k ind(s)?__________________________________________________
18q. When w as the most trea tm en t?__________________________________
18r. For how lo n g ?__________________________________________________
□  No trea tm en t (7)
18s. Tell m e why you opt NO trea tm en t?______________________________
18L How do you feel about trea tm en t?____________________________ _
18u. Tell me your cultural beliefs about treatm ent?  __________________
□  D K /R ef (9)
5
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19. What was the reason for your Hepatitis C Testing: (check all that apply)
□  Screening of Asymptomatic Patient with No Risk Factors (1)
□  Screening of Asymptomatic Patient with Risk Factors (2)
O  Blood / Organ Donor Screening (3)
□  Evaluation of Elevated Liver Enzym es (4)
□  Follow-up Testing for Previous Marker of Viral Hepatitis (5)
□  Prenatal Screening (6)
□  Symptoms of Acute Hepatitis (7)
□  If Other, please specify:___________________________________________ (8)
□  D K /R ef (9)
20. Did you experience any HCV signs/sym ptom s?
20a. Abdominal Pain □  Y es(1 ) □  No (2) □  D K /R ef (9)
20b. Arthralgia □  Yes (1) □  No (2) □  D K /R ef (9)
20c. Clay Colored Stool □  Yes (1) □  No (2) □  D K /R ef (9)
20d. Dark Urine □  Yes (1) □  No (2) □  D K /R ef (9)
20e. Diarrhea □  Yes (1) □  No (2) □  D K /R ef (9)
20f. Fatigue □  Yes (1) □  No (2) □  D K /R ef (9)
20g. Fever □  Yes (1) □  No (2) □  D K /R ef (9)
20h. Jaundice □  Yes (1) □  No (2) □  D K /R ef (9)
20i. Loss of Appetite □  Yes (1) □  No (2) □  D K /R ef (9)
20j. N ausea □  Yes (1) □  No (2) □  D K /R ef (9)
20k. Vomiting □  Yes (1) □  No (2) □  D K /R ef (9)
6
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ID Code # ______________  T oday’s  D a te :__________ / 2012 /  2013
Personal Data Collection
PATIENT HEALTH INFORMATION / HISTORY:
During the 2 weeks -  6 months prior to onset of symptoms
21. W ere you a Contact of a person with Confirmed or Suspected Acute or Chronic HCV 
infection?
Acute infection > having HCV infection tor < •  months. Chronic infection * having HCV infection for > •  months.
□  Y es(1) □  No (2) □  D K /R ef (9)
21a. If yes, w as the Contact thru: (check all that apply)
□ B lood  / Organ Donation (1) □ H ouseho ld  Member (non-sexual) (2)
□ injection  Drug Use (3) □ C o n trac ted  due to being hospitalized (4)
□O ccupational exposure (5) □  HCV mother transm its to baby (6)
□ S e x u a l /  Intimate Partner (7) Q lf Other, please specify_____________ (8)
□ D K /R e f  (9)
22. In the 6 months before symptom onset (regardless of gender /  sexual preference)
0 1 2-6 >6 Unk
22a. How many Male sex  partners did you have? D (1 ) 0 ( 2 )  0 ( 3 )  0 ( 4 )  0 5 )
22b. How many Female sex partners did you have? 0 ( 1 )  0 ( 2 )  D (3 ) Q (4 )  0 ( 5 )
22c. During those last 6  months, how many of those sex  partners did you find through the
Internet?_________________(Total #)
During the 2 weeks -  6 months prior to onset of symptoms
23. Have you EVER been treated for a Sexually Transmitted Disease/Infection?
□  Y es (1) □  No (2) □  DK / Ref (9)
23a. If yes, please specify type(s): (check all that apply)
□  Bacterial Vaginosis (BV) (1) □  Chlamydia (2)
□  Gonorrhea (3) □  HepA Virus (4)
□  HepB Virus (5) □  HepC Virus (6)
□  Herpes, Genital (7) □  HIV / AIDS (8)
□  Human Papillomavirus (HPV) / Genital W arts (10)
□  Pelvic Inflammatory D isease (PID) (11)
Q  Syphilis (12) □  Trichomonas (13)
□  Vaginitis (14) □  D K /R ef (9)
23b. Year of m ost recent specified trea tm en t?_________________________
Please, continue to next page!
7
142
ID Code # ______________  T oday’s  D a te :__________ / 2 0 1 2 / 2013
Personal Data Collection
24. Have you EVER used Street Drugs? (Smoked crack; Snorted meth, Injected cocaine)
□  Yes (1) □  No (2) □  D K /R ef (9)
25. Have you EVER used or shared a Needle or Syringe to Inject Drugs intravenously not 
prescribed by a  health care worker? (Even once)
□  Yes (1) □  No (2) □  DK / Ref (9)
26. Have you EVER used or shared Equipment to Inject Drugs intravenously not prescribed 
by a  health care worker? (Even once) (Reusing water, bottle caps, spoons, other 
containers, cotton or cigarette filters)
□  Yes (1) □  No (2) D D K /R e f  (9)
27. Has a Medical Doctor ever diagnosed you with Diabetes Mellitus?
□  Yes (1) □  No (2) □  DK / Ref (9)
27a. If yes, have you shared  your diabetic supplies i.e., finger lancets / syringes?
□  Yes (1) □  No (2) D D K  /R e f  (9)
28. Did you EVER have an Accidental Stick or Puncture with a  needle or other object 
contaminated with blood?
□  Yes (1) □  No (2) D D K /R e f  (9)
29. Have you EVER undergone /  received long-term kidney Hemodialysis (a m achine that 
removes certain w aste and chem icals in the blood when your kidney is badly injured)?
□  Yes (1) □  No (2) □  DK / Ref (9)
29a. If yes, Month and Year of hem odialysis:__________________________
30. Have you EVER received Blood / blood products [Transfusion] before July 1M2? (i.e., 
caesarean  section, maternal-child transmission, cardiac surgery)
□  Yes (1) □  No (2) □  DK / Ref (9)
30a. If yes, date of transfusion?______________________________________
31. Did you EVER reoeive any Outpatient IV Infusions and/or Injections? (Outpatient
Infusion centers provide intravenous infusions for antimicrobial therapy, therapeutic 
injections, i.e., IV antibiotics, fluid/electrolyte m anagem ent, chemotherapy, or medication 
infusion therapy and allowing you to  not be hospitalized)
□  Yes (1) □  No (2) □  DK / Ref (9)
Please, continue to next pagel
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ID Code # ______________  T oday’* D a te :__________ / 2 0 1 2 /2 0 1 3
Personal Data Collection
32. Have you EVER been in C on tac t with a P e rso n ’s  blood that had Hepatitis?
□  Yes (1) □  No (2) □  DK / Ref (9)
32a. If yes, w as the C o n ta c t (check all that apply)
□ B lood  /  Organ Donation (1) □ H ouseho ld  Member (non-sexual) (2)
□ in jection  Drug U se (3) □ C o n trac ted  due to being hospitalized (4)
□O ccupational exposure (5) □  HCV mother transm its to baby (6)
□ S e x u a l /  Intimate Partner (7) O f  Other, please specify_____________ (8)
□ D K /R e f  (9)
33. Have you EVER been E xposed  (visible o r not) to som eone e lse 's  blood that had Hepatitis?
□  Yes (1) □  No (2) □  DK / Ref (9)
33a. If yes, w as the C o n ta c t (check all that apply)
□ B lood  /  Organ Donation (1) □ H ouseho ld  Member (non-sexual) (2)
□ injection Drug U se (3) □ C on trac ted  due to being hospitalized (4)
□O ccupational exposure (5) □  HCV mother transmits to baby (6)
□ S e x u a l / Intimate Partner (7) O f  Other, please specify_____________ (8)
□ D K /R e f  (9)
34. W ere you EVER em ployed in a  M edical or Dental field involving d irec t c o n ta c t / 
ex p o su re  mucosally (eye splash, nose, m ucous m em branes) or to non-intact skin with 
human blood or infected needles?
□  Yes (1) □  No (2) □  DK / Ref (9)
34a. If yes , what w as the frequency of the direct blood contact /  exposure?
□  Frequent (several times weekly) (1) □  Infrequent (2)
35. W ere you EVER employed a s  a  Public S afety  /  E m ergency  W orker having d irec t 
co n tac t / ex posu re  mucosally (eye splash, nose, m ucous m em branes) or to non-intact 
skin with human blood or infected needles?
□  Yes (1) □  No (2) □  DK / Ref (9)
36a. If yes , p lease specify:
□  Prison / Jail / Juvenile Facility (1)
□  Fire Fighter (2)
□  Law Enforcement Officer (3)
□  If Other, please specify:_________________ (4)
36b. If yes , what w as the frequency of the direct blood contact?
□  Frequent (several times weekly) (1) □  Infrequent (2)
Please, continue to next pagel
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ID Code #  _ _ _ _ _ _ _  T oday’s  D a te :________  / 2012 / 2013
Personal Data Collection
36. W ere you EVER a  resident of a Long-Term  C are  Facility (i.e., Skill Nursing Facility)?
□  Yes (1) □  No (2) □  DK /  Ref (9)
37. W ere you EVER a resident of an Inpatien t D rug T rea tm en t P rogram ?
□  Yes (1) □  No (2) □  DK / Ref (9)
38. W ere you EVER a resident of a Halfway H ouse?
□  Yes (1) □  No (2) □  DK / Ref (9)
39. Have you EVER been Incarcerated?
□  Yes (1) □  No (2) □  DK /  Ref (9)
39a. If y es , what type of facility?
□  Prison (1) □  Jail (2) □  Juvenile Facility (3)
39b. If y es , what year w as the m ost recent incarceration?_______________
39c. For how long?___________________
40. Did you EVER receive a T attoo(s)?
□  Yes (1) □  No (2) □  DK / Ref (9)
40a. If y es , where did you receive your tattoo? (check all that apply)
□  Commercial Parlor /  Shop (1)
□  Prison / Jail /  Juvenile Facility (2)
□  If Other, please specify :________________________ (3)
41. Did you EVER have any part of your Body P ierced  (other than your ear)?
□  Yes (1) □  No (2) D D K /R e f  (9)
41a. If y es , where did you receive your body piercing? (Check all that apply)
□  Commercial Parlor / Shop (1)
□  Prison / Jail /  Juvenile Facility (2)
□  If Other, please specify :________________________ (3)
42. Have you EVER been diagnosed and / o r treated by a  Medical Doctor for H em ophilia? 
Hemophilia is a  rare bleeding disorder in which your blood doesn 't clot normally and you 
may bleed for a longer time than others after an injury. This bleeding can dam age your 
organs and tissues and may be life threatening.
□  Yes (1) □  No (2) □  DK / Ref (9)
42a. If y es , specify year:  _______________ __________
Please, continue to next page!
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Personal Data Collection
43. Have you EVER received blood clotting factor concentrates produced before 1997 in 
order to treat your Hemophilia blood disorder. Before 1987, m ost clotting factors were 
m ade from human blood can carry the viruses that cause  HIV/AIDS and Hepatitis. The 
main treatment for hemophilia is called replacem ent therapy (concentrates of clotting 
factor)
□  Yes (1) □  No (2) □  DK / Ref (9)
43a. If yes, specify y ea r:______________________________ _______________
44. Did you EVER have Dental work or Oral Surgery prior to your Hepatitis C diagnosis?
□  Yes (1) □  No (2) □  DK / Ref (9)
45. Did you EVER have Surgery (other than oral) prior to your Hepatitis C diagnosis?
□  Y es(1 ) □  No (2) □  D K /R ef (9)
46. Have you EVER received a  solid organ transplant before July 1992?
□  Yes (1) □  No (2) □  DK / Ref (9)
46a. (Organ ty p e )____________________
46b. (Enter year)  _________ _______
Please, stop here!
This concludes th is section. Thank you for taking the  




ID Code# Today’s  Date: /2 0 1 2 /2 0 1 3
Clinical Data Collection
instructions: C lin ica l d a ta  w ill b e  c o l le c te d  fro m  y o u r  M ed ica l R e c o r d , in order to 
better understand you and your Hepatitis C illness. Your health information will not link your name 
or medical record number. Thank you.
KEY: The answer choice “DK / R e f  means Don't Know or Refused to answer 
CLINICAL AND DIAGNOSTIC DATA:
1. Reason for Hepatitis C Testing: (check all that apply)
□  Screening of Asymptomatic Patient with No Risk Factors (1)
□  Screening of Asymptomatic Patient with Risk Factors (2)
□  Blood / Organ Donor Screening (3)
□  Evaluation of Elevated Liver Enzym es (4)
□  Follow-up Testing for Previous Marker of Viral Hepatitis (5)
□  Prenatal Screening (6)
□  Symptoms of Acute Hepatitis (7)
□  Other (specify)_____________________________________________ (8)
□  DK/Ref (9)
CLINICAL DATA I SYM PTOM S:
2. Hepatitis C diagnosis date: _ / /
3. Is Patient Symptomatic? □  Yes (1)
3a. If yes, onset da te :_________ /
□  No (2) □  DK/Ref (9)
4. Is /  was Patient hospitalized? O  Yes (1) □  No (2)
4a. Adm Date:______________________
4b. D/C Date:  ________________
□  DK/Ref (9)
5. Is Patient currently Pregnant? D Y e s f l )  □  No (2)
5a. Date of Delivery:______________________________
□  DK/Ref (9)
1
147
ID C o d e # ______________  Today’s  D ate; / 2012 / 2013
Clinical Data Collection
6. Did th e  patient exp erien ce?  (A nsw er for ea ch  sym p tom  below )
6a. Abdominal Pain □  Yes (1) □  No (2) □  D K /R ef (9)
6b. Arthralgia □  Yes (1) □  No (2) □  D K /R ef (9)
6c. Clay Colored Stool □  Y es(1) □  No (2) □  D K /R ef (9)
6d. Dark Urine □  Yes (1) □  No (2) □  D K /R ef (9)
6e Diarrhea □  Y es(1) □  No (2) □  D K /R ef (9)
6f. Fatigue □  Yes (1) □  No (2) □  D K /R ef (9)
6g. Fever □  Yes (1) □  No (2) □  D K /R ef (9)
6h. Jaundice □  Y es(1) □  No (2) □  D K /R ef (9)
61. Loss of Appetite □  Y es(1) □  No (2) □  D K /R ef (9)
6j. Nausea □  Y es(1) □  No (2) □  D K /R ef (9)
6k. Vomiting □  Yes (1) □  No (2) □  D K /R ef (9)
VACCINATION HISTORY:
7. Has participant ever received Hepatitis A vaccine?
□  Yes(1) □  No (2) □  DK / Ref (9)
7a. If yes, how many doses? □  1 dose (1) □  z2 doses (2)
7b. Last Hepatitis A dose  (year):______________________
8. Has participant ever received Hepatitis B vaccine?
□  Yes (1) □  No (2) □  DK I Ref (9)
8a. If yes, how many doses? □  1 dose (1) □  2 doses (2) □  3+ doses (3)
8b. Last Hepatitis B dose  (year):______________________
9. Was participant ever given bnmune Globulin?
□  Yes (1) □  No (2) □  DK/Ref (9)
9a. If yes, month/year last dose received?_________I




ID C o d e# T oday’s  Date:
Clinical Data Collection
DIAGNOSTIC TESTS:
/ 2012 /  2013
11. HAV / HBV / HCV serology results: (check all that apply)
11a. Total Antibody, Hepatitis  A Virus {total anti-HAV]
□  Positive (0) Q  Negative (1) Q  Not Done (2) □  DK / Ref (9)
11b. IgM Antibody, Hepatitis A Virus PgM anti-HAV]
□  Positive (0) □  Negative (1) □  Not Done (2) □  D K /R ef (9)
11c. Hepatitis B Surface Antigen (HBsAg]
□  Positive (0) □  Negative (1) Q  Not Done (2) □  DK / Ref (9)
11d. Total Antibody, He  pa this B Core Antigen [total anti-HBc]
□  Positive (0) □  Negative (1) □  Not Done (2) □  D K /R ef (9)
11e. IgM Antibody, Hepatitis B Core Antigen PgM anti-HBc]
□  Positive (0) □  Negative (1) □  Not Done (2) □  DK /  Ref (9)
11f. Supplemental Anti-HCV assay [e.g., RIBA]
□  Positive (0) □  Negative (1) □  Not Done (2) □  DK / Ref (9)
11g. HCV RNA [e.g., PCR]
□  Positive (0) □  Negative (1) □  Not Done (2) □  DK / Ref (9)
11h. Antibody to Hepatitis C Virus [anti-HCV]
□  Positive (0) □  Negative (1) □  Not Done (2) □  D K /R ef (9)
11i. anti - HCV signal to cut-off ratio______________
Liver Enzym e V alues: 
1 2 a .b .c . S 6 P T  (ALT)___ . Test d a te :  /_
13.a.b.c.
14.
SGOT (AST) T est d a te :  /
Other te s t(s)  i.e.. Abdominal U/S
Upper limit 
Upper limit
normal:
normal:
Genotype
Transplant List
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